"Me Too" Drugs
› Translation Needed
› Those Me-Too Drugs
› Biosimilars: Not So Dang Easy
› Pfizer's Future: Biotech Followups
› Arzoxifene: Not the Road to Big Profits?
› Now Your Liver Doesn't Have to Make It For You
› How Many PPIs Does the World Need?
› Bad Luck For Novartis - And For Diabetics
› Godzilla vs. Mothra? Relman vs. Epstein!
› By a Nose in a Head to Head
› No Clear Winners
› Gritting Our Teeth
› An Economist Who Gets It
› Alex Tabarrok on Me-Too Drugs
› Blurry Copies
› The Last Word (For A While) On Me-Too Drugs
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Hypertension and Marketing
› Merck and Its Competition
› Our Buddies at the FDA
› Adam Smith Goes Pharmaceutical
› Innovation and Its Discontents
› Claritin and Clarinex

Academia (vs. Industry)
› Academia and Industry, Suing Each Other
› Panel on Academic-Industrial Collaboration in Drug Discovery
› Francis Collins Speaks
› Does Anyone Want the NIH's Drug Screening Program?
› "The Smarter You Are, The More I Will Hate You"
› Publishing, Perishing, Buying and Selling
› How Many New Drug Targets Aren't Even Real?
› Broader Impacts Indeed
› The NIH and Conflicts of Interest
› What Translational Research Should Academia Do?
› Academic Drug Discovery: A Survey
› Roche Prevails Over Stanford
› Maybe It Really Is That Hard?
› Translation Needed
› The PhD Problem: A Global Perspective
› Nothing Personal
› Roche and Stanford: Academia v. Industry?
› What If Those Wonderful Results Are Wrong?
› The NIH Goes For the Gusto
› More On the Postdoc Situation
› A Postdoc's Lament
› Gonna Focus on Re-Engineering the Tools for the Process
› New Cures! Faster! Faster!
› The NIH's New Drug Discovery Center: Heading Into the Swamp?
› Friday Mental Health Break: "Bad Project"
› Chemistry Jobs Roundtable: What About Tenure?
› Design Your Own Lab Course
› And One Was Just Right?
› Where Drugs Come From: By Country
› Where Drugs Come From: The Numbers
› Another Set of Eyes
› A Pile of Malaria Leads For the Taking
› Reasons Not to Go to Grad School?
› All Of You Industrial Scientists: Out Of the Room
› Fear Of Academic Chemistry?
› Short Topics From All Over
› I'll See Your Conflicts, and Raise You?
› The Grant Application Treadmill
› Industrial Research: More Grounded in Reality, or Not?
› To What End?
› Just Give It to NIH
› Wasted Money, Wasted Time?
› Where Drugs Come From, and How. Once More, With A Roll of the Eyes
› More Hot Air From Me on Screening
› Competing (And Competing Unethically?)
› Poor Equipment Revisited
› The Perils of Poor Equipment
› More Than This
› Lowe's Law of Diurnal Distribution
› Getting To Lyrica
› Scrape Off Some Attitude
› Ugly, But Useful
› Drugs From Where?
› The Doctorate and Its Discontents
› Naked Synthesis
› What Can Academia Do?
› Problems and Solutions
› Peter Kim, So Far
› Not On the Same Page
› University of Drug Discovery?
› The Great Divide
› Mutual Suspicions
› Differences Between Academia and Industry, Pt. 4
› Sneaking Out for an Interview
› Getting A Job
› More on Question Four
› Getting a Faster PhD?
› The Bones of the World
› Don't Become A Scientist?
› Like Moving Furniture Across a Tightrope
› Gumming Up the Amyloid Works
› The NIH in the Clinic
› One More On Basic Research and the Clinic
› A Real-World Can O' Worms
› How Much Basic Research?
› How It Really Works
› Will the Uncommon Work for the Common Good?
› Industry vs. Academia: The Mental Aspect
› Stuart Schreiber on Stuart Schreiber
› Differences Between Academia and Industry, Pt. 2
› Differences Between Industry and Academia, Pt. 1
› On the Money

Aging and Lifespan
› Defending Das' Resvertrol Research. Oh, Come On.
› A Resveratrol Research Scandal. Oh, Joy.
› The Sirtuin Saga
› Resveratrol in Humans: Results of a Controlled Trial
› The Latest Sirtuin Controversy
› Big Sirtuin News
› SRT1720: Good (And Confusing) News for Obese Mice
› mINDY Mice - No Obesity, No Diabetes?
› Live Long and Prosper (and Be Bright Yellow at the Same Time)
› Resveratrol (SRT501): Development Halted
› Dapsone Prolongs Life? Well, In Nematodes It Does. . .
› Does Resveratrol Really Work? And Does SRT1720?
› GSK's Response to the Sirtuin Critics
› Resveratrol (SRT501): Buy Now - Why Wait?
› The Memory Goes Because. . .the Acetyl Groups Go?
› SRT501 - A Trial Suspended
› The Scent of Food Is Enough?
› Sirtris's Compounds: Everyone Agrees?
› Take These?
› Rapamycin for Alzheimer's?
› The Problem With Research on Aging
› BioTime's Cellular Aging Results
› A GSK/Sirtris Wrap-Up
› A Storm in a Teacup
› GSK and Sirtris: A Bit More
› Sirtuin Scenarios
› The Sirtris Compounds: Worthless? Really?
› Caloric Restriction and Lifespan - Without the Caloric Restriction?
› What Exactly Does Resveratrol Do?
› A Nobel for Telomerase
› mTOR, Rapamycin, and Lifespan: A Startling Study
› Exercise and Vitamins: Now, Wait A Minute. . .
› Resveratrol in Mice
› Why Buy, Anyway?
› $720 Million Worth of Sirtuin Research
› Breaking the Contract of Aging
› More Sirtuins With More Effects
› And Thee, O Time
› Sir2 Surprise
› Klotho: Sooner Than You Think?
› Breathing and Aging
› When Natural Selection's Through With You - Part II
› After Natural Selection's Through With You

Alzheimer's Disease
› Tau Spreads On Its Own?
› Bernard Munos Rides Again
› Alzheimer's: The News Is Not Getting Better
› Alzheimer's: Down With Amyloid?
› Lilly's Gamma Secretase Inhibitor for Alzheimer's: Worse Than Nothing
› Alzheimer's Markers and Collaboration
› Alzheimer's and Amyloid, Again
› Alzheimer's: Extracting Data From Failed Trials
› The Memory Goes Because. . .the Acetyl Groups Go?
› A Brief and Not At All Intemperate Evaluation of the Current Literature
› Rapamycin for Alzheimer's?
› Beta-Amyloid: An Antibiotic?
› Dimebon, Grasping at Straws
› Dimebon Comes Crashing to Earth
› A Modest Literature Proposal
› Dimebon for Alzheimer's: A Black Box Indeed
› Two Doses of Crazy
› An Alzheimer's Compound Runs Into Big Trouble
› Short Topics From All Over
› Amyloid in Trouble
› Does Glucophage Make Alzheimer's Worse?
› Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
› Where Are the Drugs?
› Rember for Alzheimer's: Methylene Blue's Comeback
› Bapineuzumab: Good For Anything or Not?
› Patents Stopping an Alzheimer's Wonder Drug?
› Another Alzheimer's Compound Goes Down
› Protecting Amyloid's Parent?
› Elan Tries Again
› In Which I Hate A Wonder Drug
› Alzheimer's: A Report From the Front
› ApoE4: Test or Not?
› Fast Plaques in a Slow Disease
› Checking The Numbers on the Alzheimer's Test
› Beta-Secretase: Not So Fast?
› Failure: Not Your Friend, But Definitely Your Companion
› How Good Is Aricept, Anyway?
› A Trial Too Far
› Gumming Up the Amyloid Works
› Silent Mutations and Noisy Ones
› Back on the Air
› Alzheimer's Vaccine Refuses to Die
› Sleeping Dragons
› Maybe They Can Formulate It in Madelaines
› Who Dares, Wins?
› Modeling the Brain?

Analytical Chemistry
› Fluorine NMR: Why Not?
› An NMR Poster
› Proteins in a Living Cell
› Fishing Around for Biomarkers
› XMRV: It's Ugly, But That's Science
› Detecting Single Cancer Cells
› NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
› Enthalpy and Entropy Again
› The Latest Technology
› Chemical Biology: Plastic Antibodies?
› Wisterone: A Structure I Can't Believe
› Chemical Biology - The Future?
› Running Your Fingers Over A Single Molecule
› Floyd Landis: The Isotopes Weren't Lying, After All
› Masses of Data, In Every Sample
› Calorimetry: What Say You?
› Sequenom: Strike Up the Music, Bring On the Cream Pies
› The Infinitely Active Impurity
› Sure About That?
› Run It Past the Chemists
› GE Healthcare's Idiotic Libel Suit
› Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
› Water and Proteins Inside Cells: Sloshing Around, Or Not?
› More Binding Site Weirdness
› A Nobel for Ribosome Structure
› Tie Me Molecule Down, Sport
› The Great Acetonitrile Shortage
› More Glowing Cells: Chemistry Comes Through Again
› You Call That An X-Ray Source?
› X-Ray Structures: Handle With Care
› Start Small, Start Right
› These Fragments I Have Shored Against My Ruins
› Mass Spec on Mars
› Floyd Landis: Could His Cortisone Treatments Exonerate Him?
› Testosterone, Carbon Isotopes, and Floyd Landis
› Doublets, Triplets, Whateverlets
› Medicine Man

Animal Testing
› The Mouse Trap
› Reboxetine Doesn't Work. But That's Not the Real Problem.
› Cancer Cells: Too Unstable For Fine Targeting?
› Charles River Buys WuXi
› Animal Studies: Are Too Many Never Published At All?
› Fat Rats Make Poor Test Subjects?
› Animal Testing: A View From the Labs
› Animal Rights, You Say?
› Animal Models: How High to Set the Bar?
› Whose Guess Is Better?
› The Animal Testing Hierarchy
› Unacceptable
› Less Than Zero
› Worst Animal Model: Nominations Are Open
› Formally Undecideable
› Rats Rule, Right?
› Ends, Means, Rats, and Dogs
› Model Systems, From Inside and Out
› Furry Judges, With Tails
› What to Do When the Rats Die on You
› Rats, For Fear of Worse
› You'll Only Get Answers
› Modeling the Brain?

Autism
› What Autism Epidemic?
› MMR Vaccine and Autism: Lies, All Lies
› Vaccines in the Court
› Autism and Vaccines: Boiling Over Yet Again
› Thimerosal. Again.
› Thimerosal, Again
› A Mechanism for Thimerosal
› Here and There
› Compare and Contrast
› The Rate of Autism
› Clearance Sale
› Thimerosal - A Chemical Point
› Thimerosal - a Chemical Point
› Clearance Sale
› A Quick Tour Through the Mudhole
› More on Autism (And Mercury)
› More on Autism and Mercury
› A Quick Tour Through the Mudhole
› Neurotoxins
› Neurotoxins
› Doing Justice to Thimerosal, And the Story
› Doing Justice to Thimerosal, and the Story

Biological News
› Roche Goes Hostile for Illumina
› Fun With Epigenetics
› Warp Drive Bio: Best Name or Worst?
› Osiris And Their Stem Cells
› Brain Cells: Different From Each Other, But Similar to Something Else?
› Proteins in a Living Cell
› Geron, Stem-Cell Pioneers, Drop Stem Cells
› Cyclodextrin's Day in the Sun
› The Latest Sirtuin Controversy
› Big Sirtuin News
› Merck, RNAi, Alnylam, And So On
› Bait And Switch For Type B GPCRs
› A First Step Toward A New Form of Life
› The Histamine Code, You Say?
› The Uses of Disorder
› Garage Biotech: The Book
› Biomarkers, Revisited. Unfortunately.
› Get Yer Telomeres Measured, Step Right Up
› Smell The Vibrations? Fruit Flies Might Be Able To. . .
› Fishing Around for Biomarkers
› Arsenic Bacteria: Does The Evidence Hold Up?
› Roche Has Problems - But RNA Interference Has More
› And Now, the Retractome
› Epigenetics: The Code Isn't The Object
› TRIM21: A Cure For the Common Cold? Maybe Not. . .
› Are Genes Patentable Or Not?
› Laser Nematode Surgery!
› More on Garage Biotech
› Chemical Biology: Engineering Enzymes
› Chemical Biology - The Future?
› Vinca Alkaloids, And Where They End Up
› Reverse-Engineering the Human Brain? Really?
› Maybe We Should Make It More of a Game
› Craig Venter, Venting
› XMRV and Chronic Fatigue: You Thought You Were Confused Before
› Stable Helical Peptides Can Do It All?
› A Synthetic Genome; A New Species
› Rosetta@Home
› Curse of the Plastic Tubes
› The Scent of Food Is Enough?
› Homemade Morphine?
› Masses of Data, In Every Sample
› Let's Sequence These Guys
› ACC2: Great Metabolic Target, Or Total Bust?
› Rapamycin for Alzheimer's?
› Sickened by an Engineered Virus?
› What Do Nanoparticles Really Look Like?
› GeneVec's Pancreatic Cancer Therapy Crashes
› Nanoparticles and RNA: Now In Humans
› A Bit More Garage Biotech
› BioTime's Cellular Aging Results
› Stem Cell Politics
› The PSA Test for Prostate Cancer: Useless
› Garage Biotech
› A GSK/Sirtris Wrap-Up
› Your Own Personal Bacteria
› The Plasmid Committee Will See You Now
› Biology By the Numbers
› Enzymes and Fluorines
› Receptors, Moving and Shaking
› Maybe You Need Some More Testosterone Over There
› An Enzyme Inhibitor You Have Never, Ever, Considered
› Correlations, Lovely Correlations
› MAGL: A New Cancer Target
› Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
› Extortion, Retractions, And More
› Five Technologies For the Scrap Heap?
› Run It Past the Chemists
› Water and Proteins Inside Cells: Sloshing Around, Or Not?
› What Exactly Does Resveratrol Do?
› Nanotech Armor
› Engineering Receptors: Not Quite There Yet. Not Exactly.
› A Nobel for Ribosome Structure
› A Nobel for Telomerase
› Antioxidants and Cancer: Backwards?
› Right Where You Want Them
› Still Semaphoring, Even From the Bottom of the Swimming Pool
› Schematic Notation for Biology?
› Dealing With Hedgehog Screening Results
› What's So Special About Ribose?
› Genzyme's Virus Problems
› Exercise and Vitamins: Now, Wait A Minute. . .
› Niacin, No Longer Red-Faced?
› No MAGIC Involved
› Genes to Diseases: Hard Work, You Say?
› The Motions of a Protein
› Grabbing Onto A Protein's Surface
› Gene Expression: You Haven't Been Thinking Big Enough?
› Wash Your Tubes; Mess Up Your Data
› System Biology: Ready, or Not?
› Fructose In The Brain?
› More Glowing Cells: Chemistry Comes Through Again
› A Green Fluorescent Nobel Prize
› Antipsychotics: Do They Work For A Completely Different Reason?
› New, Improved DNA?
› Receptors: Can't Live With 'Em, Can't Understand 'Em
› Killing Proteins Wholesale
› Empty As Can Be
› Nanotech Stem Cells, Order Now!
› RNA Interference: Even Trickier Than You Thought
› Getting Real With Real Cells
› Rainbows and Fishing Expeditions
› Avandia: Going Under for the Third Time?
› A Real Genetic Headscratcher
› What We Don't Know About Enzymes
› Checking The Numbers on the Alzheimer's Test
› Let Us Now Turn To the Example of Yo' Mama
› More Things Than Are Dreamt Of
› Visfatin: Real Or Not?
› It Went Up Instead of Down
› Peptides as Texts
› Neowater Replies
› Nanotech Wonder Water?
› Stem Cell Disaster
› Grand Rounds Today, and Next Week
› RNAi: The Awkward Age
› Kinases and Their Komplications
› The Vapor Trail I Referred To
› It's a Bacterial Planet, You Know
› There'd Better Not Be an Argon Receptor
› All Bets Are Now Officially Off
› A New Cancer Target - Maybe
› Proteinocentrism
› Gene Therapy Decisions

Birth of an Idea
› Open Source Science?
› Vial Thirty-Three, And More
› Back on the Air
› Vial Thirty-Three: Warp Drive
› The Race Is On
› Publish, Then Perish
› The Horse Latitudes
› Good News, Now That I Think About It!
› Back To Life
› Vial Thirty-Three: The Third Run
› Vial Thirty-Three Rides Again
› Vial Thirty-Three: One Up, One Down
› Mid-day Update
› Minute by Minute
› Vial Number Thirty-Three
› Cliff Diving
› A Scientist's Resolutions
› Report From What I Think is the Frontier
› Experimental News
› News Flash: I May Not Be a Fool
› Data, At Last
› Experimental Update
› Experimental Update, For Those Who Care
› Live The Stereotype!
› The Consolations of Pure Research
› Don't Talk To Yourself So Much
› Mismatched Socks
› A Little Ambiguity Would Be Welcome Right About Now
› Dr. Lowe? I Have Your Hypothesis on Line Two
› If This Doesn't Work, There's Only Reality To Fall Back On
› Good News, Backing Slowly Through the Door?
› Waiting for the Metaphorical Phone to Ring
› Per Fits and Starts, Ad Astra
› Here It Goes
› Nature Stood Me Up
› Close to the Vest
› Close To the Vest
› Experimental Update
› In Case Anyone's Wondering
› Back for More
› Meanwhile, Back at the Chocolate Factory
› The Nuts and Bolts of a New Idea
› Measure Twice, Cut Once

Blink ›
› Nature Doesn't Care: Latest in a Series
› Vaccines by the Dozen
› Follow Which Money Where?
› An Experiment in Progress?
› Alex Tabarrok on Me-Too Drugs

Blog Housekeeping
› Comments (And Everything Else) Are Back
› Comment Trouble
› Ten Years of Science Blogging. Already?
› Media Note
› Holiday Break
› Blog Traffic: A Thank-You
› A "Things I Won't Work With" Request
› Happy Thanksgiving
› Lab Preparation: Key Lime Pie
› Conferencing
› Conference Travel, With Blogging
› Day Off - Some Links and Some Ancient Greek
› What An Offer
› Back to Blogging
› On and Off
› Memorial Day
› Inadvertent Day Off
› Conference Time
› Day Off
› Another Snow Day
› Snow and Chance Happeneth To Them All
› Another Cold-Weather Recipe: Chicken Pot Pie
› A Cold-Weather Recipe, By Request: Onion Soup
› Weather Delay
› Holiday Break
› Blogging Break
› Holiday Organic Synthesis: Chocolate Pecan Pie
› Open Thread
› Day Off
› Blogroll Update
› Housekeeping Note
› Lunch at the Boston ACS Meeting
› By The Way. . .
› Out in the Public
› Back in Business
› Midsummer
› More From the Fourth
› Holiday
› Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
› Coming Soon
› Chemistry In (Ahem) Everyday Life
› Delivery Via Kindle
› Of Cambridge, MA Interest Only
› More on C&E News
› Day Off
› More Blogroll
› Blogroll Update
› Blog Traffic - Thanks!
› Write A Book, Why Don't You
› Twitter and Science, Revisited
› Sure Thing
› Physics, for Dogs and Others
› Holiday Time Off
› Day Off!
› Another Blogroll Update
› Light Blogging
› Applied Organic Synthesis: Chocolate Pecan Pie
› More For the Blogroll
› A Blogroll Update
› "Back to School"
› Day Off
› Traveling, Updates Later
› Traffic Record
› Back
› Time to Sing the Alma Mater
› H-h-h-holy C-c-c-c-cow
› Blogroll Update
› Return From Travel: A Note About Cheaptickets.com
› Travel Continues. . .
› Travel
› Day Off
› Blogroll Update
› Proxy Server Update
› Proxies for Iran (More Politics - Mixed With Technology)
› And Now Some Politics
› Quick Blogroll Update
› Blog Contestification
› Blog Contestiness
› A Science Writing Award
› Still More Blogroll Additions
› Blogroll Update
› More Travel!
› San Diego
› Travel
› Blogs and Journalism
› Hexacyclinol - Another Request
› Day Off
› The Blogroll
› Holiday Break
› How Slow is Research Today? Here's a Recipe!
› Day Off
› Back
› Time Off
› Happy Fourth of July
› Leaving Comments: A Fix
› Explaining It All
› Quick Note
› Anonymity?
› Day Off
› Commenting Issues
› Back On the Air
› Snow Day
› Synthetic Prep of the Day: Chocolate Pecan Pie
› Holiday Break
› Bright Lights and Applause?
› Blogroll Update
› Meet the Blogger?
› Not Necessarily So
› Two Weeks Off
› Real Life, Which Costs Real Money
› But Enough About You
› Blogroll Update
› Linkage!
› Back From DC
› You Want Me to Just Talk? No Problem.
› Comments on Comments
› Blogroll Update
› Back on the Air
› Work At Home! It's Easy; It's Fun!
› Holiday Schedule
› Shameless Self-Promotion
› Elsewhere
› Watch This Space
› Links and Such
› Darn Photons
› Here and There
› A Friday Linkfest
› Back on the Air
› Travel
› Linkorama
› Missed One!
› A Lengthy Day
› Technical Difficulties
› Blogroll Revamp
› Various Updates
› Comments Welcome - Really
› Instead of Working
› Procrastination Assistance
› Outside Reading, and Plenty of It
› And Another Thing. . .
› Blogging About Science Blogging
› Even More Worthwhile Stuff
› Like, Er, Fine Wine. I Hope.
› Summer Hours
› Continued Slacking
› Outside Reading
› New Address
› One Problem Solved, Anyway
› A Technical Question
› And Now A Word. . .
› Schedule Update
› Holiday Blogging
› Stocking Stuffers, of a Sort
› Now With The Great Taste of Fish
› Comment Problems
› Two Days Off (From This, Anyway)
› No Coming Attractions Here
› A Question For the Audience
› Summer Hours
› The Last Word on Taste
› Categories
› Welcome Back!
› Catching Up
› Here and There

Book Recommendations
› Brain Cells: Different From Each Other, But Similar to Something Else?
› A New Book on Chemical Patents
› Data Handling in Collaborations
› Book Review: The Quest for the Cure
› Garage Biotech: The Book
› Drug Discovery History
› Serendipity in Medicine
› Friday Book Recommendation
› Friday Book Recommendation
› A Friday Book Recommendation
› Physics, for Dogs and Others
› Recommended Books For Medicinal Chemists, Part One
› Business Books: The Enantiomers
› A Med-Chem Book Recommendation
› Inspirational Reading?

Business and Markets
› The Terrifying Cost of a New Drug
› Buying Back Shares: An Admission of Defeat
› AstraZeneca in Waltham
› AstraZeneca Layoffs and Closings
› AstraZeneca Cutting Even More?
› Roche Goes Hostile for Illumina
› Alnylam Cuts Back Hard
› Takeda Announces Cuts
› Warp Drive Bio: Best Name or Worst?
› Newhouse Research
› Sanofi's Bridgewater Site - Closing This Week?
› Welcome To the Jungle! Here's Your Panther.
› The JP Morgan Myths
› SciFinder Access For the Unemployed
› Osiris And Their Stem Cells
› 2012 In Startups
› That's Sir Andrew to You
› More From Hua - A Change of Business Plans?
› Merry Christmas, Fred
› AstraZeneca's Problems
› Deals of the Year in Biopharma (Bonus: Names That Can't Happen)
› More on Chinese Pharma Espionage
› Chinese Pharma Espionage?
› Pharma Overview
› The Loss of the Middle (Drugs and the People Who Find Them)
› Merck in China
› Novartis: No More Neuroscience
› More on Alex Denner
› Acronym-Fest: GSK and Its DPUs
› Worst Biotech CEO of 2011?
› So What Did Lipitor Do for Pfizer? Or Its Shareholders?
› Of Drug Research and Moneyball
› Business Note: Random Promotion, Anyone?
› Ray Firestone's Take On Pharma's Plight
› Virtual Pharma, Revisited
› Managing For Motivation, The Simple Way
› Exit Icahn, Enter Denner?
› Geron, Stem-Cell Pioneers, Drop Stem Cells
› In-Sourcing Chemistry: Lilly and AMRI
› Verastem Goes Public: Why Not?
› Sanofi Announces Layoffs
› Exelixis Fights City Hall, and City Hall Looks Like Winning
› A Note About Identity Spoofing
› Merck, And What Used to Be Schering-Plough
› Novartis Announces Cutbacks
› NCPharma: Changing the Drug Industry How, Exactly?
› The Layoff Project
› Abbott Cuts the Drug Business Loose
› Reorg at Merck? (And a Complaint about Wall Street)
› Amgen: Brace Yourselves
› So, How Come You're So Darn Lucky, Eh?
› What Layoffs Have Done
› GSK and McLaren: Two Different Worlds
› China's Home-Grown Insanity?
› China's Pharma Ambitions: Hua Pharmaceuticals Responds
› Chinese Pharma: No Shortage of Ambition, Anyway
› The NIH Wonders About the Future of Biomedical Workers
› Is Carl Icahn Going Away?
› Lundbeck Cutting R&D
› The Economics of the Drug Industry: Big Can't Be Big Enough?
› Bernard Munos Rides Again
› Dendreon: Watch the Cost Curve Being Bent
› A Former Pfizer Executive Finally Trashes Pfizer's Strategy
› Merck, RNAi, Alnylam, And So On
› Merck Announces More Big Cutbacks
› The Secret History of Pfizer
› Innovation and Return (Europe vs. the US)
› Pfizer Reverses Course in Sandwich - A Bit
› Drug R&D Spending Now Down (But Look at the History)
› Not Looking So Good At Eli Lilly (or AstraZeneca)
› How's All That Cost-Cutting Working Out?
› Block That Review
› Another Two-Person Drug Company
› Extreme Outsourcing
› Pfizer's Brave New Med-Chem World
› Pfizer's Layoff Dance
› Get Yer Telomeres Measured, Step Right Up
› Imperfect Pitch
› Icahn's Biotech Adventure
› A Look Inside the Compound Collections
› Pfizer: Breaking Up Is Hard to Do
› Merck: How to Spend the Money
› Pfizer Layoffs Today
› AstraZeneca Tears 'Em Down
› Now They Tell Us
› Nothing Personal
› Merck and J&J Finally Come to Terms
› Coming Up in the World With CROs
› Total Pharma Job Cuts
› R&D Is For Losers?
› What's Really Killing Pharma
› Westphal Leaves GSK
› Insider Trading at the FDA
› The Supreme Court Slams Big Pharma? Not Exactly.
› The Small Drug Companies And the Big Ones
› Brave New Office
› More Bad News in the UK: Novartis Horsham
› Pfizer Moves Antibacterials to Shanghai
› Pfizer: Bigger, Um, Isn't Better?
› What A Fool Believes
› The Pfizer Air Force
› The Costs of Drug Research: Beginning a Rebuttal
› A Postdoc's Lament
› MannKind: It's Not Looking Good
› The Pfizer Sandwich Closure
› Is Big Pharma Killing Startup Companies?
› Want to Live Where Merck Used to Work?
› Cutting The Cuts to Save Money on the Money-Saving
› The Key Player in the Sanofi-Genzyme Deal Speaks Out
› Merck, J&J, and Remicade: Waiting Nervously
› The Top 200 Drugs
› Fanapt: Not Paying Out
› Too Much Outsourcing: Has the Line Been Crossed?
› Whistleblowers: Paid Too Much?
› Not Letting Pfizer's UK Site Go to Waste?
› Merck's Strategy vs. Pfizer's
› Pfizer's CEO Speaks
› Pfizer Part Two: Cuts at Groton
› Bad News: Pfizer Closes Site in Sandwich
› Abbott's Cutting Jobs
› Merck's Thrombin Antagonist In Trouble
› Sanofi's Slow-Motion Takeover of Genzyme
› Ahem: "Sell Gobs of Dope"?
› The PhD Problem
› How to Fund a Nonprofit Drug Company - And Others?
› Jobs Roundtable Recap
› Science Jobs Roundtable - Day Four
› Chemistry Jobs Roundtable: What About Tenure?
› Too Many PhDs, Revisited
› Big Pharma's Lost Stock Market Decade
› Chemistry Jobs, Present and Future
› Have Pfizer's Investors Had Enough?
› Exit Kindler
› Novartis, Meet Novartis (Job Cuts or Not?)
› More Advice From Andrew Witty
› Of Deck Chairs, Six Sigma, And What Really Ails Us
› Roche Has Problems - But RNA Interference Has More
› Comment of the Day: Outsourcing and Architecture
› An Outsourcing Blast
› Where Drugs Come From: By Country
› Where Drugs Come From: The Numbers
› Merck vs. J&J: Wait For It
› Exelixis Grabs A Life Preserver
› The Layoff Picture
› Spamming For Site Shutdowns. Sheesh.
› Sanofi Goes Hostile
› Sanofi-Aventis: It's $69/Share, And That's Where It Stays
› Merck vs. J&J: It's Come to This, Eh?
› Outsource to China, Then Move There?
› China Outsourcing: Getting More Expensive, Fast?
› Roche: Layoffs, or Rumors?
› How About The Same Price You Turned Down Before? Hmm?
› Sanofi-Aventis and Genzyme: Walking Away?
› Going Hollywood
› Reporting on Alternative Careers
› Is Genzyme a Buyable Company At All?
› MannKind and Seaside 88?
› If You're Not A Chemist - What Next?
› All Quiet on the Genzyme Front?
› Know How to Make Praziquantel? Tell The World.
› Charles River Gives Up
› Let's Just Spread This Deal Out All Over the Paper, Why Don't We?
› New from OSI / Astellas
› Genzyme: On the Other Hand. . .
› How Sleazy It Can Get
› Genzyme Telling Sanofi-Aventis to Buzz Off?
› Biosimilars: Not Easy, But Not Impossible, Either
› Aventis: Is It Genzyme?
› Hmmm: The Gates Foundation Bails
› Lechleiter's Prescription for Science
› Why Close One Research Site Over Another?
› Merck Site Announcements - Closures and Otherwise
› Drug Prices in the US: Not So High After All?
› Sanofi-Aventis Acquires. . .Somebody?
› GSK's Biotechy World
› That Schering-Plough Lawsuit Isn't Going Away
› Andrew Witty's Advice
› Chemistry Employment in New England?
› The Economic Impact of the Genomic Revolution's Failure
› Checking the Business Ratios
› Merck Layoffs - Underway?
› Paying People to Take Their Medications
› Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
› Albany Molecular Cuts - In the US, Anyway
› "Better Educated" in China?
› India's Research Culture
› Astellas and OSI: Nothing like MLNM/Takeda?
› Manning the Phones
› Astellas Buys Out OSI
› Layoff at Takeda
› China's Future
› Perverse Incentives In Clinical Trials
› Intermune: Right Back Down Again
› Merck Rumors?
› The Collapse of Complexity
› Treatment INDs - For Any Generex Fans Out There
› Sirtris's Compounds: Everyone Agrees?
› Merck Closes a Site
› Charles River Buys WuXi
› Two Bad Ideas
› Generex: Who Buys This Stuff, Anyway?
› A Re-Org at Novartis
› A Tiny Little Presentation Tip
› Colchicine's Price Goes Through the Roof
› Novartis, Roche Threaten To Leave the UK
› Too Many Consulting Jobs Work This Way
› Prediction Markets, Idea Sharing, and So On
› The Crowd Goes Wild
› Pfizer's Golden Age
› Generex and Their Insulin Spray: Just Hype?
› Let's Hope They're Right
› Exelixis: Hmmmm.
› If You Need Some Lab Equipment. . .
› BioTime's Cellular Aging Results
› Lilly Layoffs Today?
› Intermune's Rise
› Hope Darn Well Springs Eternal
› Bad News at Exelixis
› Merck/Schering-Plough People?
› Twelve and One Half Per Cent
› AstraZeneca Makes Its Move
› Layoffs Coming at Eli Lilly?
› Layoff News
› Knocking on Doors
› Merck Announces Cuts
› Drug Patents in India
› Picking Up Industrial Hires
› Sanofi-Aventis Cuts Back
› Where Would You Start a Company?
› More On Pharma's Ugly Finances
› Sheer Economics: How We Got in This Fix
› BMS Freezes Salaries
› GSK Day
› And on the Carl Icahn Front. . .
› GSK: More Cuts Coming
› Merck and Sirna
› Your First Pharma Bloodletting of 2010: AstraZeneca
› Sequenom: Strike Up the Music, Bring On the Cream Pies
› Honesty, Of A Sort
› The Sirtris Compounds: Worthless? Really?
› Carl Icahn Going For Genzyme?
› Always Read the Fine Print
› The Cost of New Drugs
› Another Take on the Munos Paper
› Munos On Big Companies and Small Ones
› Pfizer's R&D Productivity
› Drug Companies Since 1950
› Pfizer's Pearl River Layoffs
› Merck, Shopping in the UK?
› Go Spread It On the Rosebushes
› Against Panic
› Telling the Layoff Story
› Pfizer's Chemistry Head Count - Really?
› Pfizer's Site Closures - An Analysis
› Pfizer's New Layout
› Selling It, And Selling It Hard
› Thoughts on What Used to Be Schering-Plough
› J&J Raises the Ax
› In Which You Get to Hear the Phrase "Hatch-Waxman" Again
› Fifty Years of Scientific History For You
› The Best Ones Aren't Over Here Any More?
› You Mean You Don't Have to Buy Them?
› Red Flags in Biotech
› Pfizer's People
› O Brave New World! That Has Such Companies In't!
› What Pfizer Will Look Like in a Year
› Short Topics From All Over
› "Day One" at Pfizer
› Which Pfizer / Wyeth Sites Will Close?
› The Drug Business: A Turbulent Future?
› Lilly Shrinks
› Pharma Whistleblowing: How It Works
› Sepracor: A Desirable Property?
› A 2.3 Billion Dollar Attention-Getter
› Lexapro, Forest Labs, and the Hard Sell
› Drug Companies Are Polar Bears? Maybe Not.
› Pharma's Return on Investment: Yikes
› Ghostwriting
› Savient Feels The Pains of Gout
› Where Drugs Come From, and How. Once More, With A Roll of the Eyes
› Drug Approvals, Natural And Unnatural
› Incompetence, Avoided?
› Too Many Scientists?
› How Much Does the Drug Industry Spend on Marketing?
› Vanda Comes Back From the Dead
› Voluntary, You Say?
› Meanwhile, Over At Sanofi-Aventis. . .
› GSK's Getting Better. Just Ask the CEO.
› One. . .Billion. . .Dollars!
› Perpetual Patents: A Nasty Thought Occurs
› CafePharma Will Now Approach The Bench
› Will The Gentleman With the Pitchfork Please Speak Up?
› A Deuterium Deal
› Akt and Mek, But Not PDQ
› Arena, Lorcaserin, and the FDA
› J&J Lowers the Boom
› Arena / Lorcaserin Update
› San Francisco Biotech: Holding Up, or Not?
› Goldman Sachs: Out Of the Drug Funding Business Already?
› Kumbaya
› Merck, Elsevier, and Fakery
› Genentech: Let's Hope He's Right
› Dendreon's Stock: What the Hey?
› Dendreon's Revenge?
› Pfizer's New Structure: Good Luck To All
› Biogen Idec: What's Going On?
› Layoffs At Merck
› And That Is That
› Roche / Genentech: The Chase Is Over
› Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
› The Merck Deal and the SEC: Not a Joke
› Merck Actually Does It
› Single, Simple Numbers: Use At Your Own Risk
› Genentech's Culture: At Risk or Not?
› Business Books: The Enantiomers
› Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
› Roche / Genentech: So There is a Deadline
› How Long Is Roche Prepared to Wait?
› Short Business Notes: AstraZeneca, Biogen, Vertex
› Short Business Note: GSK's At Least Not Going to Merge
› Sir James Black Vents, Therapeutically
› Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
› Roche Goes Hostile - Or Does It?
› Opportunity Costs
› Pfizer and the Credit Crunch
› Pfizer / Wyeth: Different This Time?
› Pfizer / Wyeth: They're Going to Take Us All Down With Them
› Nitromed: Someone Wants Them
› With A Straight Face, Yet
› Lilly Pays the Price
› More on Pfizer's Layoffs
› Why Pfizer?
› Layoffs. More Layoffs.
› Insider Trading in Drug Stocks? Not Unknown. . .
› The Worst Biotech CEO?
› Pfizer's Restructuring Grinds Along
› Goldman Sachs: A New Drug Research Model?
› Roche Stalls For Time
› Two Drugs in One? Maybe Not.
› The Back Door to the Stock Market
› Pfizer: Strategy, Layoffs, and Money
› Lilly And Imclone: Not Expensive Enough!
› Cutbacks - But Not As Bad This Time
› Merck Cuts Back (Again)
› Imclone Really Does Get Bought
› Eli Lilly and Imclone: Sensible? Real?
› Hard Times: A Manifesto
› Various Drug Industry News, None of It All That Good
› Imclone's Secret Admirer
› Pfizer: As We Speak?
› Ranbaxy: Cutting Corners, or Falsely Accused?
› BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
› US and UK Biotech: Growth and Form
› Pfizer / Bayer?
› Direct To Consumer Ads: Wasted Money?
› RNAi: Bubble or Not?
› Genentech and Roche, Act Two
› Roche Palo Alto: What's Going On?
› Job Seekers: Genentech, GSK, and Elsewhere
› GSK Layoffs: Yes, Again
› Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
› Should Genentech Be a Part of Roche?
› Vytorin: Another Round of Nasty Results
› Sharing the Enlightenment
› More on Outsourcing
› Pfizer's Prospects: Just Ducky
› Alli: "Underwhelming"
› Suits vs. Lab Coats?
› More On the GSK Layoffs
› GSK: Money-Green Outside, Pink-Slip Inside
› A Breath of Fresh Air from Fuji
› Nullius in Verba
› Awash in Yen
› Cordaptive Q and A
› Why Buy, Anyway?
› $720 Million Worth of Sirtuin Research
› Free Sushi in the Cafeteria!
› A Solution, Courtesy of the MIT Faculty
› Hits, Misses, and Some More Misses
› How Many PPIs Does the World Need?
› Drugs and Money
› Laissez-Faire?
› Cheap Happiness
› Drugs and Money and How It Feels
› Dollar, Drugs, and Advertising
› Top of the Heap
› Hearing Footsteps
› Biogen's Not For Buying. For Now.
› Med-Chem Layoffs, On the Front Page
› More Belts Tighten
› How You Doin'? How's Everybody Doin'?
› Lights, Camera, Pharma!
› Come On. Improve, Already.
› Surveying the Exubera Crater
› Biogen on the Block?
› More Layoffs, And What They Might Mean
› Hey, Graduates! Negotiate Hard, You Hear, Now?
› Good News From the HR Department!
› Have We Got A Deal For You!
› Guess That Market
› Oh, Come On
› Ah, Rumors
› Buying What You Can't Make? Or What?
› Exubera Spirals Toward the Drainpipe
› European Drugs, American Drugs
› Knowing What You Know. . .
› Alas, Dendreon
› Outsourcing Blues?
› Put Your Money Down
› Layoffs - Again
› Amgen: The Pythian Oracle Laughs Again
› Buy! Sell! Shout! Moan!
› Vaccines Everywhere
› Vectibix Lurches A Bit
› Schering-Plough Goes Shopping
› Biotech's Net Loss?
› A Good Day's Work
› Good Sense Breaks Out, Film at Eleven?
› BMY-SNY?
› The Big Picture
› Pfizer's Pfinances
› Novo Nordisk Axes Med-Chem
› ICOS In Pieces?
› Pfizer's Sizing
› Sell! (It's Not Just Me)
› Help Wanted - I Hope
› Chinese Med-Chem - In China, For Once
› Hope, Springing Eternal And All That
› You Can't Make Money If You Don't Get Paid
› Blow The Trumpets
› Up Periscope And Fire All Bow Tubes
› Imclone, Drama Queen of Biotech
› Tough Targets
› Walking the Plank at Bristol-Myers Squibb
› Merck: Unfigure-outable
› The Great Plavix Disaster
› Pfizer's Man at the Top
› Pfizer Recalculates
› The Sun Shines at Pfizer
› Getting and Spending
› J&J Shrinks Their Labs Again
› Neurocrine's Choice
› The Fur Continues to Fly
› What's German For "Food Fight"?
› Leadership Secrets of the Data Fudgers
› Full Disclosure
› Golden Parachute, Still Packed and Ready
› Rioting for Unemployment
› Can You Say "Uebernahmeangebot"?
› Nitromed's Slow Decline
› More on Outsourcing
› J&J Shakes Things Up
› Forecast: Rain, Eventually
› Imclone Revisited
› The Tar Pit Beckons
› James Cramer, Biocryst, and You
› Human Genome Science Hits the Wall
› Where Do the Good Ones Go?
› The Check Shows Up in the Mail. Really.
› Pfizer Opens Their Wallet - Again
› You Figure It Out
› Public Utility, You Say?
› Punching the Clock at Merck
› What Ails the Germans?
› The Globalization of Med-Chem
› Drug versus Stock
› Waiting for the FDA
› Glaxo v. Pfizer: Sales Force Stand-Down?
› Pfizer's Prospects
› Maybe They Should Fire Them All?
› Optioning the Drug Portfolio
› Don't Ask; Just Trade
› Let's See What the Sharks Think of These Steaks!
› Could I Have a Side Order of Risk With That?
› Public Utility, You Say?
› How Bad Are the Cox-2 Inhibitors, Anyway?
› A Day With All the Bark Left On It
› Rank and Yank?
› Measure for Mismeasure
› Around and About
› Another Shot Across the Bow
› Vox Populi
› As Goes ASCO. . .
› A Capacious Rat-Hole Indeed
› Deferred Gratification Is Better Than None At All
› Yahoots
› Foaming Up Over the Edge
› Bulking Up
› Thou Hast It Now. . .
› Play It Again
› Tasty New Recipes for the Root of All Evil
› Quis custodiet ipsos custodes?
› Pravachol vs. Lipitor Update
› Mismatched Socks
› Ignorance Was Bliss
› I will do such things - What they are yet I know not. . .
› Allons Pharmas de la Patrie!
› . . .Your Huddled Pharmas Yearning to Breath Free
› Ah, Marketing
› Mismeasure for Mismeasure
› Measure for Measure
› What Sort of Number Did You Have in Mind?
› O Brave New Market, That Has Such Medicines In It
› Bad News at a Bad Hour of the Night
› Caveat Lector
› Muddying the Water For Fun and Profit
› Back For Some More
› Marketing Ueber Alles
› By Any Other Name
› The Apatosaurus. The Spruce Goose. The Pyramids
› The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
› A Less-Than-Subtle Plan

Cancer
› Academia and Industry, Suing Each Other
› (Un)stoppable Pixantrone
› Zelboraf: Treat One Cancer, Speed Up Another?
› Fun With Epigenetics
› AstraZeneca's Problems
› Burzynski Revisited
› Podcast on Avastin
› The Burzynski Cancer Treatment
› The Mouse Trap
› Avastin Coverage, Amended
› Avastin's Metastatic Breast Cancer Approval Revoked
› Brain Cells: Different From Each Other, But Similar to Something Else?
› Geron, Stem-Cell Pioneers, Drop Stem Cells
› Verastem Goes Public: Why Not?
› Medivation Comes Through With MDV3100
› Exelixis Fights City Hall, and City Hall Looks Like Winning
› Avastin: False Hope for Metastatic Breast Cancer
› Too Many Cancer Drugs? Too Few? About Right?
› So, How Come You're So Darn Lucky, Eh?
› Terra Slightly Less Incognita
› A Startlingly Good Leukemia Trial
› More On Cancer Drug Shortages
› Dendreon: Watch the Cost Curve Being Bent
› The Duke Cancer Scandal and Personalized Medicine
› Avastin and Medicare
› Avastin At the FDA Today: Passion Should Lose
› The Evolution of Resistance: Are We Doing It Wrong?
› A Shortage of Cancer Drugs?
› The Ethics of Avastin
› Off the Beaten Track. Way, Way, Off.
› More Zeroing In On Breast Cancer Cells
› So, You Thought Breast Cancer Was Complicated?
› Oncology Follow-Up Trials
› New Cures! Faster! Faster!
› Sanofi's PARP1 Inhibitor Misses
› Not Enough Progress Against Cancer?
› Detecting Single Cancer Cells
› The Avastin Decision: A Reality Check
› Resveratrol (SRT501): Development Halted
› Halaven: Holder of the Record
› Is Cancer A Disease of the Modern World?
› Princeton's New Chemistry Building
› PLX4032: The Good News and the Bad News
› Metformin Against Cancer?
› Avastin For Metastatic Breast Cancer: The Whole Story
› Avastin: Taking It Back
› Cancer Cells: Too Unstable For Fine Targeting?
› Exelixis Gets a Compound Back
› Mylotarg and the FDA
› Angiotensin Receptor Blockers and Cancer: For Real?
› Ipilimumab (And Progress Against Cancer)
› Again, What's It Worth to You?
› Eribulin Gets Reviewed, Finally
› The Power of Photons, You Say?
› DCA And Cancer: More Results
› Malcolm Gladwell on Synta and Oncology
› Environmental Cancer?
› Perverse Incentives In Clinical Trials
› SRT501 - A Trial Suspended
› Masses of Data, In Every Sample
› GeneVec's Pancreatic Cancer Therapy Crashes
› Antisoma's Phase III Disaster
› Diminishing Returns
› The Problem With Research on Aging
› Nanoparticles and RNA: Now In Humans
› The PSA Test for Prostate Cancer: Useless
› HER2 Confusion
› The Front Lines of Cancer Treatment
› MAGL: A New Cancer Target
› Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
› A Nobel for Telomerase
› Antioxidants and Cancer: Backwards?
› Thalidomide for Myeloma: Whose Idea Was It?
› Wasted Money, Wasted Time?
› Avastin's Numbers
› Akt and Mek, But Not PDQ
› But You Can't Make Them Take It?
› Angiogenesis Inhibitors: Helping or Hurting?
› Into the Clinic. And Right Back Out.
› Dendreon's Stock: What the Hey?
› Dendreon's Revenge?
› The Motions of a Protein
› Kinases: Hot or Not?
› Curse Of the Lost Compounds
› Sunesis: No Substitutions Allowed?
› BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
› The Complicated Causes of Cancer
› GSK Layoffs: Yes, Again
› Vytorin: Another Round of Nasty Results
› Auroral Activity
› And You Thought Exubera Was A Disaster Before
› Whose Guess Is Better?
› Judah Folkman
› Plants For Cancer?
› Bacterial Infection: Better Or Worse Than Cancer?
› Arsenic, Patents, and the World
› The Current Cancer Long-Jump Record
› Phase Zero?
› Let A Thousand Flowers Bloom
› Amgen: The Pythian Oracle Laughs Again
› Awful, No Doubt. But Not As Awful as Before?
› Vaccines Everywhere
› Failure: Not Your Friend, But Definitely Your Companion
› Vectibix Lurches A Bit
› A Good Day's Work
› Good Mistakes?
› An Innocent Question
› Reality, Here In This Little Dish
› Sell! (It's Not Just Me)
› Blow The Trumpets
› Here and There
› Imclone, Drama Queen of Biotech
› Tell 'Em You Work On Something Else
› Resistance Isn't Quite Futile
› That Fount of Information We Call ASCO
› Jungle Rot
› New Frontiers in Self-Deception
› Price Gouging or Not?
› Gold and Lasers
› What's It Worth to You?
› Mice, Humans, and Cancer
› Another Shot at Cancer
› The Hard News on Cancer
› Hype or Hope?
› No Such Disease
› Selectivity: One of Those Flexible Concepts
› A Tale of Two Trials
› Cancer Delusions
› When the Alternative is Nothing
› Biotech At Last, Eh?
› That Has to Be Good, Right?
› ASCO Fever
› 'Tis the Season
› The Price of Desperation
› Targretin's Troubles
› Drug versus Stock
› Still Not All That Easy
› Springtime for Oncology
› What We Are Pleased to Call State of the Art
› Black Friday: One Damn Thing After Another
› The Coming Oncology
› Check, Please
› Tarceva Targets
› Clay Lies Still, But Blood's A Rover
› Costs and Benefits, Risks and Rewards
› Another Shot Across the Bow
› Bungee Jumping with PPAR Drugs
› It'll Cost You
› Vox Populi
› As Goes ASCO. . .
› All the Myriad Ways
› Deferred Gratification Is Better Than None At All
› Yahoots
› Foaming Up Over the Edge
› A New Cancer Target - Maybe
› Back on the Air
› Pneumonia, of All Things
› O Brave New Market, That Has Such Medicines In It
› Not Even Funny
› Genetic Optimism
› The Wall Street Journal versus the FDA
› Consequences of Aneuploidy
› Aneuploidy, or What're A Few Chromosomes, More or Less?
› HER-1 And HER-2, Too
› Save Your Tears
› A Few Words
› Did He Say What They Thought He Said?
› Now Is the Peptide of Our Discontent
› Hype and Glory
› More Imclone, More Food for Thought
› A Certain Tension in the Air
› Imclone in Progress

Cardiovascular Disease
› Lipitor Expiration Day
› Regeneron Finally Makes It to the Market
› Pushing Onwards with CETP: The Big Money and the Big Risks
› Geron, Stem-Cell Pioneers, Drop Stem Cells
› Anticoagulants, One After Another
› A Few More Victories Like This, And We Will Be Undone
› Cardiac Hope and Cardiac Hype
› Niacin's Unexpected Flop
› Fenofibrate: Good For Much?
› Phase II Failures
› Merck's Vorapaxar: Bleeding, Indeed
› Merck's Thrombin Antagonist In Trouble
› Merck's CETP Compound: Still Alive, But The Big Fun Awaits
› Apotex's Plavix Adventure: Four Years Later
› Avandia: Was the Evidence Buried?
› That Schering-Plough Lawsuit Isn't Going Away
› Lilly's Statin - Yes, It Is 2010
› Angiotensin Receptor Blockers and Cancer: For Real?
› Raising Your HDL - Through the Brain?
› Pfizer Halts a Trial Early - On Good News
› Steve Nissen vs. GlaxoSmithKline
› Animal Studies: Are Too Many Never Published At All?
› Diminishing Returns
› Tricor's Troubles
› Steve Nissen's Meeting with GSK
› Remember Apo-A1 Milano? Pfizer Does.
› Plavix vs. Effient
› Zetia Takes Another Torpedo
› Placebos Can Work the Other Way, Too
› Statin Safety?
› Rolofylline Hits the Skids
› CafePharma Will Now Approach The Bench
› Mipomersen - It Still Works
› Exercise and Vitamins: Now, Wait A Minute. . .
› Farewell to ACAT, and to Lots of Time and Money, Too
› Niacin, No Longer Red-Faced?
› The Polypill Rides Again
› Takeda Gets A Surprise
› Torcetrapib: What Was the Problem? And Does It Matter?
› Crestor: Would It Save Any Lives?
› Crestor: Risks Up, Risks Down
› Prasugrel Today?
› Vytorin: Another Round of Nasty Results
› Prasugrel: Come Back This Fall
› Merck, Vioxx: Seventeen and Three
› In Which I Hate A Wonder Drug
› Cordaptive Q and A
› Another Cholesterol Medication Goes Down (Or Does It)?
› Whose Guess Is Better?
› Vytorin Numbers
› Vytorin: It's A Pity
› Pfizer vs. the NEJM: A Legal Showdown
› Off Target? Which Target Did You Mean?
› A Look Under the Hood
› Vytorin, Holed Under the Waterline
› Renin, Wherefore Art Thou, Renin?
› Rimonabant, Out In the Light
› The Avandia Wars Continue
› More Avandia, And More on Marketing
› Avandia: Trouble or Not?
› The HDL Compost Pile
› AGI-1067: Dead or Alive?
› Torcetrapib: The Foil-Lined Hat Perspective
› Bigger And Greasier
› Too Near the Sun?
› The Torcetrapib Catastrophe
› Pfizer's Sizing
› Ah, the Heck With the Error Bars
› Elsewhere
› It Should Work. It Just Doesn't.
› Plavix Plot Twists
› Merck: Unfigure-outable
› The Great Plavix Disaster
› Pfizer Recalculates
› More Statin Skirmishing
› Vioxx: 18 Months to Trouble?
› As Merck Caroms Off Another Tree
› Merck and the Numbers
› Merck's Latest Underwhelming Data
› The New England Journal And Its PR Flacks
› Merck, So Far
› Nitromed's Slow Decline
› The Big Statin Pillow Fight
› NEJM vs. Its Contributors, Round Two
› Merck versus the New England Journal
› Does Celebrex Have A Future At All?
› An Expensive Way Back for Celebrex
› The New England Journal of Legal Immunity?
› Selectivity: One of Those Flexible Concepts
› Merck on Trial
› Where's the Combo?
› A Drug's Target, Finally
› COX-2 Aftermath
› Waiting for the FDA
› Boarding Up the Windows
› The FDA Weighs In
› Let's See What the Sharks Think of These Steaks!
› Cox-2 Confusion
› How Bad Are the Cox-2 Inhibitors, Anyway?
› More on Merck
› A Day With All the Bark Left On It
› The Last Word (For A While) On Me-Too Drugs
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Pravachol vs. Lipitor Update
› Ignorance Was Bliss
› Ezetimibe, The Press, and More
› The Beginning? It's Right Past the End. . .
› Sic Transit Gloria Mundi
› Trials of Trials
› Cholesterol Lowering, One Way or Another

Chem/Bio Warfare
› The Litvinenko Case: More On Polonium and Alpha Particles
› Evil Thoughts of Evil Things
› A Fire, And Its Flames
› Osmium Tetroxide, Of All Things
› Ricin Redux
› More Ricin
› Ricin
› And While We're On the Subject - Mercury?
› A Mystery Gas?
› Chemical Warfare, Part Five: The Real World
› Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
› Chemical Warfare, Part Three: How Nerve Agents Work
› Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
› Chemical Warfare, Part One: Introduction

Chemical Biology
› Screening Quickly Through the Mutants
› A First Step Toward A New Form of Life
› Chemical Biology: Engineering Enzymes
› Chemical Biology: Plastic Antibodies?

Chemical News
› Glass Structure, Atom by Atom
› Potassium Hydride Is Not Your Friend
› Lead-Oriented Synthesis - What Might That Be?
› The UCLA Lab Fatality: Criminal Charges Filed
› Chemistry, The Movie!
› Trifluoromethylation, The Easy Way?
› An NMR Poster
› Now That's A Catalyst
› Nothing Says "Chemistry" Like Nonsense!
› Finding Even More New Reactions By Looking For them
› Georgia Tech Forgets How to Draw Structures
› Brow-Furrowing Chemical Ads
› A Quasicrystal Nobel Prize
› Pulling Molecules Apart, For Fun
› Finding New Reactions By Looking For Them
› Terra Slightly Less Incognita
› Fifty Years of Med-Chem Molecules: What Are They Telling Us?
› Get Yer Rhodanines Here
› Crazy Shape-Shifting Bullvalenes
› New Ways to Fluorinate
› Bait And Switch For Type B GPCRs
› Precious Metal Time
› The Public Perception of Chemistry
› Will Macrocycles Get It Done?
› Getting Rid of Pesky Chirality
› Like Charges, Er, Attract?
› Quis Custodiet Ipso Custodes?
› Process Chemistry Makes the Headlines
› In Memoriam, Two Chemists
› What Medicinal Chemists Really Make
› In Which I Do Not Lose It, For Once
› Smell The Vibrations? Fruit Flies Might Be Able To. . .
› The Solid Phase
› Not On My Street - I Hope
› Going to Let Someone Else Do This One
› Halaven: Holder of the Record
› Finally, An Alternative to Palladium. About Time.
› ACS Survey - Or Something Else?
› Graphene Oxide as a Reagent
› Princeton's New Chemistry Building
› Back to Philadelphia
› Meeting Time
› A Nobel For Palladium Couplings, At Last
› Chemical Biology: Engineering Enzymes
› Chemical Biology: Plastic Antibodies?
› Wisterone: A Structure I Can't Believe
› Nobel Season 2010
› Delightful, But It Apparently Works
› Chemical Biology - The Future?
› Synthetic Chemistry: All Mined Out?
› Want To Make an Amide? Have I Got Good News For You!
› Sodium Hydride As Oxidant, Again?
› Ancient Chemistry Comes Back to Life?
› Organic Chemistry: A Lack of Challenges?
› Metal-Free Coupling Reactions: Now Wait A Minute. . .
› Running Your Fingers Over A Single Molecule
› Know How to Make Praziquantel? Tell The World.
› Another Zero-Palladium Delusion?
› The Ideal Synthesis
› Maitotoxin: It's On, All Right
› Sparteine and Other Fine Chemical Shortages
› Max Gergel's Memoirs
› What's the Condensation Record?
› Pyridines and Dichloromethane
› You Don't See Many Names Starting with "Tellura-"
› Maitotoxin Revisited
› Report from C&E News
› Nonsense About LSD
› Flowing, Not So Gently
› Together At Last
› Sure About That?
› More Binding Site Weirdness
› K. C. Nicolaou, Call Your Office
› Hoist, Petard, Etc.
› Retire These Reactions!
› Microwaves Aren't Magic
› Nobel Season 2009
› Chew On This, Enzyme
› More on T2, and Degrees
› 175 Times. And Then the Catastrophe.
› "Scratch and Sniff" Turns Into "Zap and React"
› Another Iron Reaction Hits The Mat
› Rings of the Future!
› Everything In Its Place
› The Further In You Go, The Bigger It Gets
› Devils, Metals, and Details
› TMS Diazomethane: Update On a Fatality
› Writing With Triazoles
› The Motions of a Protein
› Grabbing Onto A Protein's Surface
› Your Paper Is A Sack Of Raving Nonsense. Thank You.
› Hexacyclinol - Another Request
› Hexacyclinol: A Forensic Case
› The Original Nanotechnology
› A Long Tail Indeed
› The Real Hazards of the Lab
› The Great Acetonitrile Shortage
› Diversity-Oriented Synthesis: Oriented The Right Way?
› Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
› An Impressive Nanolist of Nanocitations
› Copper: A Gentleman's Disagreement
› New Tricks With Glassware
› DNA Forklifts, DNA Pliers
› Le Dernier Cri
› One For the Brave
› Ertl Wins: Down With Witchcraft
› All Sorts of Holes
› Steve Ley, Azadirachtin, and Me (Very Much in That Order)
› ACS Meetings
› Calcium: A Backwater
› Smell the Vibrations
› Six Chem-Geek Questions
› Hexacyclinol Rides Again
› Hexacyclinol? Or Not?
› Chem-Geek Alternate History
› A New Route to Tamiflu?
› More on Woodward
› Archaeologists Announce Dirty Laundry Discovery
› Why Total Synthesis?
› Climbing Mountains

Clinical Trials
› Reaction to Andy Grove's Clinical Trial Proposals
› Rexahn Rides Again
› Targacept's Antidepressant Fails, And How
› Medivation Comes Through With MDV3100
› Exelixis Fights City Hall, and City Hall Looks Like Winning
› Too Many Cancer Drugs? Too Few? About Right?
› Andy Grove's Idea For Opening Up Clinical Trials
› Bernard Munos Rides Again
› Laquinimod Fails For Multiple Sclerosis
› The Duke Cancer Scandal and Personalized Medicine
› An Unethical Clinical Trial
› Making the Numbers Confess
› Niacin's Unexpected Flop
› The Ethics of Avastin
› Fenofibrate: Good For Much?
› Phase II Failures
› Lucentis and Avastin: Results
› Update on Avastin and Lucentis
› More on KV and Makena's Pricing
› Makena's Price: What to Do?
› The Cost to Develop a Drug: Your Own Numbers?
› That $43 Million R&D Figure
› The Costs of Drug Research: Beginning a Rebuttal
› Use Avastin! Don't Use Avastin!
› Down In Phase III. Again.
› Oncology Follow-Up Trials
› Sanofi's PARP1 Inhibitor Misses
› Not Enough Progress Against Cancer?
› Merck's Vorapaxar: Bleeding, Indeed
› Reboxetine Doesn't Work. But That's Not the Real Problem.
› Merck's Thrombin Antagonist In Trouble
› Detecting Single Cancer Cells
› Resveratrol (SRT501): Development Halted
› Of Deck Chairs, Six Sigma, And What Really Ails Us
› Merck's CETP Compound: Still Alive, But The Big Fun Awaits
› Trusting the Medical Literature?
› Avastin: Taking It Back
› Cancer Cells: Too Unstable For Fine Targeting?
› Alzheimer's Markers and Collaboration
› Resveratrol (SRT501): Buy Now - Why Wait?
› Alzheimer's and Amyloid, Again
› Vivus, Qnexa, Arena, Lorcaserin and the FDA
› Avandia: Was the Evidence Buried?
› Alzheimer's: Extracting Data From Failed Trials
› Pfizer Halts a Trial Early - On Good News
› DCA And Cancer: More Results
› Perverse Incentives In Clinical Trials
› Steve Nissen vs. GlaxoSmithKline
› SRT501 - A Trial Suspended
› A Landmark In Clinical Trial Data Interpretation
› Ardea's Gout Drug Progresses
› Animal Studies: Are Too Many Never Published At All?
› GeneVec's Pancreatic Cancer Therapy Crashes
› Antisoma's Phase III Disaster
› Diminishing Returns
› Nanoparticles and RNA: Now In Humans
› Benford's Law, Revisited
› Tricor's Troubles
› Intermune's Rise
› Hope Darn Well Springs Eternal
› Dimebon, Grasping at Straws
› Dimebon Comes Crashing to Earth
› HER2 Confusion
› Steve Nissen's Meeting with GSK
› The Front Lines of Cancer Treatment
› Dimebon for Alzheimer's: A Black Box Indeed
› A Database of Side Effects
› Correlations, Lovely Correlations
› Sirtuin Scenarios
› Lilly's R&D Outsourcing
› An Alzheimer's Compound Runs Into Big Trouble
› All Of You Industrial Scientists: Out Of the Room
› Plavix vs. Effient
› Zetia Takes Another Torpedo
› Massaging the Data for Neurontin?
› Placebos Can Work the Other Way, Too
› Arzoxifene: Not the Road to Big Profits?
› Wasted Money, Wasted Time?
› Amyloid in Trouble
› Medarex, Ipilimumab, Prostate Cancer, And Reality
› Avastin's Numbers
› Rolofylline Hits the Skids
› CafePharma Will Now Approach The Bench
› Akt and Mek, But Not PDQ
› Arena, Lorcaserin, and the FDA
› Surrogate Markers Are Awful, But They're Ours
› Goldman Sachs: Out Of the Drug Funding Business Already?
› Into the Clinic. And Right Back Out.
› Farewell to ACAT, and to Lots of Time and Money, Too
› Another Obesity Drug? Not Likely.
› Lilly's Latest Loses (This Time)
› And While We're Talking About Industry-Sponsored Studies. . .
› What Results Did You Have In Mind?
› Drug Industry Research: Reliable or Not?
› Want A Hard Disease Target? Try Lupus
› Maribavir, Ouch
› New Year - I Hope!
› Goldman Sachs: A New Drug Research Model?
› Torcetrapib: What Was the Problem? And Does It Matter?
› Avandia: Trouble, Run Head to Head
› Two Drugs in One? Maybe Not.
› Crestor: Would It Save Any Lives?
› Crestor: Risks Up, Risks Down
› Down The Chute in Phase III
› Rember for Alzheimer's: Methylene Blue's Comeback
› Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
› Vytorin: Another Round of Nasty Results
› Glaxo Asks the Eurocrats
› Another Alzheimer's Compound Goes Down
› Fun With Bacteria
› And You Thought Exubera Was A Disaster Before
› Another Cholesterol Medication Goes Down (Or Does It)?
› Vytorin: It's A Pity
› You Get What You Pay For?
› Taranabant in Trouble?
› Hits, Misses, and Some More Misses
› Antidepressants: Depressing News or Not?
› A Look Under the Hood
› Vytorin, Holed Under the Waterline
› Come On. Improve, Already.
› Deactivation, After All
› Rimonabant: Down to Earth
› Rimonabant, Out In the Light
› Phase Zero?
› Pecunia Non Olet?
› The Avandia Wars Continue
› Knowing What You Know. . .
› Avandia: Trouble or Not?
› Deep Breaths
› Vectibix Lurches A Bit
› FDA Advisory Panels: Pay, No Play
› AGI-1067: Dead or Alive?
› Vertex, Hepatitis, and Gripping the Arms of Your Chair
› Upside Down Activity
› Torcetrapib: The Foil-Lined Hat Perspective
› Too Near the Sun?
› The Torcetrapib Catastrophe
› It Should Work. It Just Doesn't.
› A Spray-Painted Crystal Ball
› Tough Targets
› Tegenero, In Detail
› Vioxx: 18 Months to Trouble?
› Formally Undecideable
› A Question For the Crowd
› Access to Phase I Drugs: A Constitutional Right?
› A Word to the Wise About TGN1412
› TNG1412: Was There a Warning?
› Update on TGN1412
› No Immunity From Immunity
› But His Name Lives On. . .
› The FDA Loosens Its Tie
› An Expensive Way Back for Celebrex
› Rigel's Puzzling Failure
› This Had Better Be Good
› By a Nose in a Head to Head
› No Clear Winners
› Muraglitazar's Turn
› Gritting Our Teeth
› Where's the Combo?
› Still Not All That Easy
› The NIH in the Clinic
› One More On Basic Research and the Clinic
› How It Really Works
› Unburied
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Fast, Cheap, and Sometimes Even Good
› Primum Non Nocere, Eh?
› The Journals Fight Back
› Your One-Stop Clinical Data Superstore?
› Cue the Music
› Pravachol vs. Lipitor Update
› Ignorance Was Bliss
› More From the Me-Too Front
› Putting A Price on Proving It
› Here and There
› Trials of Trials
› Statins and Multiple Sclerosis
› Muddying the Water For Fun and Profit
› Save Your Tears

Closing Time
› Med-Chem Layoffs, On the Front Page
› Massachusetts Moving
› A Post I've Been Looking Forward to For Months
› Layoffs - Again
› More Help Wanted?
› Have We Got a Job For You!
› A Break, Whether I Felt Like It Or Not
› Open For Business
› Ghost Town
› Out With the Old
› Cleans Down to What Should Be the Shine
› Hi, My Name Is [...]
› The Paper Mountain
› Vial Thirty-Three: Warp Drive
› Where Do All The Chemicals Go?
› The Race Is On

Current Events
› Science, A Zero-Sum World, and the State of the Union
› More on Chinese Pharma Espionage
› The Force of Cluelessness
› A Brief Note on Current Events
› A Radiation Chart to Clip and Save
› Potassium Iodide Pills
› Quick Japan Update
› Bias And How to Deal With It
› Japan
› Science and Revolution
› Health Care Reform and the Drug Industry: How Goes It?
› And a Quick Political Note
› Lethal Injection: A Case For the FDA?
› Martin Gardner, RIP
› Floyd Landis: The Isotopes Weren't Lying, After All
› Report from C&E News
› Bits And Pieces
› Sir James Black, 1924-2010
› The Health Care Bill: A Therapeutic Rant
› Theft at Eli Lilly
› Pharma and the Health Care Bill: Value For the Money?
› Sanofi-Aventis Cuts Back
› Here's a Business Plan For You
› GSK Day
› A Scorched-Earth Policy at Wyeth's Princeton Site?
› GE Healthcare's Idiotic Libel Suit
› Once You Have Paid Him the Danegeld. . .
› Climategate and Scientific Conduct
› Warren DeLano
› Prof. Keith Fagnou
› Against Panic
› A Nobel for Ribosome Structure
› A Nobel for Telomerase
› The Details of the Baucus Bill
› Pay Them Now, Or Pay For It Later
› Norman Borlaug
› The PhRMA Deal
› PhRMA's Negotiating Game
› Health Care Reform - Really?
› Iran: Politics and Technology Update
› Proxy Server Update
› Proxies and Politics Again
› Politics: Proxy Servers Revisited
› Proxies for Iran (More Politics - Mixed With Technology)
› And Now Some Politics
› Will The Gentleman With the Pitchfork Please Speak Up?
› But You Can't Make Them Take It?
› Kumbaya
› Faking It on Facebook
› Don't Hit The Bunkers Just Yet
› Biogen Idec: What's Going On?
› Sponsor A Gene?
› Layoffs At Merck
› Greedy Biotechs?
› Wyeth v. Levine: Pre-emption Goes Away
› Ranbaxy in Trouble
› Single, Simple Numbers: Use At Your Own Risk
› Autism and Vaccines: Boiling Over Yet Again
› Their Crime? Collaborating With Other Scientists. . .
› Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
› Well, Hose Me Down. . .
› Layoffs. More Layoffs.
› Pfizer's Restructuring Grinds Along
› We Interrupt This Science. . .For Some Politics
› BlackLight Power Responds
› Blacklight Power: What on Earth?
› A Green Fluorescent Nobel Prize
› Nobel Season 2008
› Pfizer: As We Speak?
› More Pfizer Layoffs?
› Nullius in Verba
› Judah Folkman
› Ah, Politics
› Unnatural, And Proud Of It
› Ertl Wins: Down With Witchcraft
› Nobel Chemistry Odds
› Nobel Season
› The Choir Hears It Again
› Pour Encourager Les Autres
› Access To Science
› Time To Conduct Some Business
› Layoffs - Again
› Hedgehogs in Stockholm
› F. A. Cotton, 1930-2007
› CMPI Conference: Critical Path
› CMPI Conference: Lunch With the FDA
› CMPI Conference: Panel on the Politics of Drug Evaluation
› CMPI Conference: Panel on Media Coverage
› That Smell
› And The Winner Is. . .
› Injustice
› The Litvinenko Case: More On Polonium and Alpha Particles
› Polonium Poisoning
› Help Wanted - I Hope
› Here and There
› Floyd Landis: Could His Cortisone Treatments Exonerate Him?
› Airplanes and Chemicals
› Testosterone, Carbon Isotopes, and Floyd Landis
› Explosion News
› Poor Put-Upon Intelligent Design
› The Dover Decision Comes Down
› Merck Update
› Merck, Finally
› Intelligent Design, Molecule By Molecule
› The Dover Decision
› Merck Off the Mat
› Metathesis Nobel!
› A Piece of the Action
› Okay, One More Merck Point
› No More Merck For A Couple of Days
› Judgement Day
› Welcome to the World, I Hope
› Strangers on a Train
› Special Off-Topic Weekend Irrelevancy
› Actually, It's Everything Else That's Off-Topic
› Happy Fourth of July
› Osmium Tetroxide, Of All Things
› And Another Thing. . .

Diabetes and Obesity
› Dapagliflozin Goes Down (For the Last Time?)
› More From Hua - A Change of Business Plans?
› Regeneron Finally Makes It to the Market
› SRT1720: Good (And Confusing) News for Obese Mice
› mINDY Mice - No Obesity, No Diabetes?
› GSK and Alli. Not Quite Working Out
› MannKind: It's Not Looking Good
› Lorcaserin's Complete Response
› Avandia Goes Down: A Research Rant
› Live-Blogging Arena's FDA Committee Hearing
› Lorcaserin in Trouble
› MannKind and Seaside 88?
› PPAR: A Veil Is Lifted, At Last
› Vivus, Qnexa, Arena, Lorcaserin and the FDA
› Avandia: Was the Evidence Buried?
› Insulin Degrading Enzyme's Turn in the Spotlight
› Steve Nissen vs. GlaxoSmithKline
› Treatment INDs - For Any Generex Fans Out There
› Generex: Who Buys This Stuff, Anyway?
› The Crowd Goes Wild
› ACC2: Great Metabolic Target, Or Total Bust?
› Generex and Their Insulin Spray: Just Hype?
› Rats and High-Fructose Corn Syrup
› Tricor's Troubles
› Your Own Personal Bacteria
› Steve Nissen's Meeting with GSK
› Avandia: Off the Market or Not?
› Sirtuin Scenarios
› Gaining and Losing and Discovering and Selling
› MAGL: A New Cancer Target
› Obesity: Hope Springs Eternal (Summer 2009 Version)
› Obesity Shows Up in the Death Rate? Right?
› Arena, Lorcaserin, and the FDA
› Arena / Lorcaserin Update
› Exercise and Vitamins: Now, Wait A Minute. . .
› A DPP-IV Compound Makes It Through
› Another Obesity Drug? Not Likely.
› Takeda Gets A Surprise
› Does Glucophage Make Alzheimer's Worse?
› Avandia: Trouble, Run Head to Head
› CB-1 Obesity Drugs: Farewell to the Whole Lot
› Fructose In The Brain?
› Taranabant Is No More
› Metabolic Hope Springs Eternal
› All The Fat Cells You'll Ever Have - Sort Of
› Alli: "Underwhelming"
› Merck Bails on Natural Products
› Why Buy, Anyway?
› Exubera, Safety, and No Guarantees
› And You Thought Exubera Was A Disaster Before
› Whose Guess Is Better?
› Taranabant in Trouble?
› Off Target? Which Target Did You Mean?
› More On Merck and Taranabant
› What You Become Known For
› Eat It, Breath It, Soak in It?
› Avandia: Going Under for the Third Time?
› Bad Luck For Novartis - And For Diabetics
› Depressing Figures for Acomplia
› Surveying the Exubera Crater
› More Things Than Are Dreamt Of
› Buying What You Can't Make? Or What?
› Exubera Spirals Toward the Drainpipe
› Deactivation, After All
› Visfatin: Real Or Not?
› Right Down the Alli
› Rimonabant: Down to Earth
› Rimonabant, Out In the Light
› The Avandia Wars Continue
› More Avandia, And More on Marketing
› Avandia: Trouble or Not?
› Exubera: This Time With Feeling
› Rimonabant, Slowly
› You Can't Make Money If You Don't Get Paid
› Up Periscope And Fire All Bow Tubes
› The Inscrutable French
› Neuropeptide Y Dies, But It Never Surrenders
› Tell 'Em You Work On Something Else
› Rimonabant Arrives
› What's French for "Trust Us"?
› Rimonabant Bangs Into. . .Something
› Pfizer Takes a Deep Breath
› Ghrelin and Obestatin
› Pargluva Goes Down?
› This Had Better Be Good
› Waiting for Pargluva
› Muraglitazar's Turn
› Gritting Our Teeth
› Symlin, At Last
› Worries about Rimonabant?
› Bungee Jumping with PPAR Drugs
› Why Own the Car, When You Can Own the Road?
› Ah, Marketing
› Of All Sad Words. . .
› Fighting City Hall
› A Treadmill Pill?
› Enzymes, Right and Wrong

Drug Assays
› The Infinitely Active Impurity
› Fluorine NMR: Why Not?
› Do We Believe These Things, Or Not?
› Lead-Oriented Synthesis - What Might That Be?
› Riding to the Rescue of Rhodanines
› Rating A Massive Pile of Compounds
› Francis Collins Speaks
› Does Anyone Want the NIH's Drug Screening Program?
› Different Drug Companies Make Rather Different Compounds
› Lilly's Open Screening Program: An Update
› Get Yer Rhodanines Here
› How Many New Drug Targets Aren't Even Real?
› Kibdelomycin, A New Antibiotic. In A Way.
› Is Anyone Doing the Pfizer Screening Deal?
› Bait And Switch For Type B GPCRs
› Phenotypic Screening For the Win
› In Which I Do Not Lose It, For Once
› A Look Inside the Compound Collections
› Fragments Versus DOS: A Showdown
› The NIH's New Drug Discovery Center: Heading Into the Swamp?
› And One Was Just Right?
› Enthalpy and Entropy Again
› Laser Nematode Surgery!
› A Cautionary Tale
› Chemical Biology: Plastic Antibodies?
› GSK's Response to the Sirtuin Critics
› Natural Products: Not the Best Fit for Drugs?
› Masses of Data, In Every Sample
› Charles River Buys WuXi
› Take These?
› Animal Studies: Are Too Many Never Published At All?
› Compounds and Proteins
› Privileged Scaffolds? How About Unprivileged Ones?
› Privileged Scaffolds
› Drugs And Their Starting Points
› We Don't Know Beans About Biotin
› Tricor's Troubles
› Garage Biotech
› Why You Don't Want to Make Death-Star-Sized Drugs
› Calorimetry: What Say You?
› Two For One Sale
› Polluting the Literature with PAINs
› Merck and Sirna
› The Infinitely Active Impurity
› GSK and Sirtris: A Bit More
› The Sirtris Compounds: Worthless? Really?
› Run It Past the Chemists
› Selective Scaffolds
› Why Don't We Have More Protein-Protein Drug Molecules?
› More Binding Site Weirdness
› Side Effects, Predicted?
› Lumpy Assay Results
› What Exactly Does Resveratrol Do?
› To What End?
› Dealing With Hedgehog Screening Results
› Drug Approvals, Natural And Unnatural
› Why Does Screening Work At All? (Free Business Proposal Included!)
› Eli Lilly Gives It Away
› More Hot Air From Me on Screening
› Want To Screen Pfizer's Compounds? Sign Here.
› No MAGIC Involved
› Drugs For Bacteria: Really That Hard, Or Not?
› Tie Me Molecule Down, Sport
› Structure-Activity: Lather, Rinse, and Repeat
› The Hideous Numbers of Compounds
› Diversity-Oriented Synthesis: Oriented The Right Way?
› Sticking It to Proteins
› Wash Your Tubes; Mess Up Your Data
› Animal Models: How High to Set the Bar?
› X-Ray Structures: Handle With Care
› Receptors: Can't Live With 'Em, Can't Understand 'Em
› Sharing the Enlightenment
› Oops
› The Miracle Solvent
› Whose Guess Is Better?
› Start Small, Start Right
› Getting Real With Real Cells
› The Animal Testing Hierarchy
› These Fragments I Have Shored Against My Ruins
› A Bad Assay: Better Than None?
› Let Us Now Turn To the Example of Yo' Mama
› The Current Cancer Long-Jump Record
› Travels In Numerica Deserta
› Less Than Zero
› No Shortcuts
› Good Mistakes?
› Upside Down Activity
› Reality, Here In This Little Dish
› The Unattractive Truth
› Those Darn Invisible Creatures
› Waste O' Time Awards
› More on Voodoo
› And 0.04 Molar in Eye of Newt. . .
› Everything's Under Control, Right?
› Seven Questions
› What Makes A Target, Anyway?
› Compounds for the Sake of Compounds
› Oh, Dear
› Too Interesting For Us
› Model Systems, From Inside and Out
› What Ails Us
› The Vapor Trail I Referred To
› Our Cheerful Buddy, The Cell Membrane
› Ezetimibe, The Press, and More
› The Beginning? It's Right Past the End. . .
› How Drugs Die
› A Request From Biology
› Ratio Rationalizations
› That Voodoo That We Do

Drug Development
› The Terrifying Cost of a New Drug
› Putting a Number on Chemical Beauty
› Fun With Epigenetics
› Biogen: A "Decimated" Pipeline?
› Welcome To the Jungle! Here's Your Panther.
› Do We Believe These Things, Or Not?
› Lead-Oriented Synthesis - What Might That Be?
› More From Hua - A Change of Business Plans?
› The Sirtuin Saga
› Drugs, Airplanes, and Radios
› Riding to the Rescue of Rhodanines
› Pushing Onwards with CETP: The Big Money and the Big Risks
› "You Guys Don’t Do Innovation. The iPad. That’s Innovative"
› Francis Collins Speaks
› A Note to Andy Grove
› Harvard to the Rescue
› Too Many Cancer Drugs? Too Few? About Right?
› Different Drug Companies Make Rather Different Compounds
› How Many New Drug Targets Aren't Even Real?
› GlaxoSmithKline Reviews the Troops
› Chinese Pharma: No Shortage of Ambition, Anyway
› Bernard Munos Rides Again
› 2011 Drug Approvals Are Up: We Rule, Right?
› Will Macrocycles Get It Done?
› Phenotypic Screening For the Win
› Innovation and Return (Europe vs. the US)
› Drug R&D Spending Now Down (But Look at the History)
› What Translational Research Should Academia Do?
› Extreme Outsourcing
› Pfizer's Brave New Med-Chem World
› Maybe It Really Is That Hard?
› Imperfect Pitch
› Process Chemistry Makes the Headlines
› What Medicinal Chemists Really Make
› Translation Needed
› Off the Beaten Track. Way, Way, Off.
› R&D Is For Losers?
› Your Comments on the NIH's CNS Drug Program?
› The NIH Goes For the Gusto
› Value in Structure?
› More on KV and Makena's Pricing
› Makena's Price: What to Do?
› The Cost to Develop a Drug: Your Own Numbers?
› That $43 Million R&D Figure
› The Costs of Drug Research: Beginning a Rebuttal
› Down In Phase III. Again.
› Gonna Focus on Re-Engineering the Tools for the Process
› New Cures! Faster! Faster!
› Drug Problems: A Diagnosis
› Fragments Versus DOS: A Showdown
› The NIH's New Drug Discovery Center: Heading Into the Swamp?
› What's the Most Worthwhile New Drug Since 1990?
› Oh, And While You're At It. . .
› Merck's Vorapaxar: Bleeding, Indeed
› Merck's Thrombin Antagonist In Trouble
› Gassing Your Crystals
› How to Fund a Nonprofit Drug Company - And Others?
› More Advice From Andrew Witty
› Of Deck Chairs, Six Sigma, And What Really Ails Us
› And One Was Just Right?
› Where Drugs Come From: By Country
› Where Drugs Come From: The Numbers
› Trusting the Medical Literature?
› Chemical Biology: Engineering Enzymes
› Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
› GSK's Response to the Sirtuin Critics
› Going Hollywood
› Cancer Cells: Too Unstable For Fine Targeting?
› Open-Source Pharmaceutical Babble
› Fungal Structures to the Rescue
› Exelixis Gets a Compound Back
› Flibanserin: Not a "Female Viagra" At All
› The Economic Impact of the Genomic Revolution's Failure
› The Atlantic Monthly on Drug Pipelines
› Another Set of Eyes
› Biosimilars: Not So Dang Easy
› Malcolm Gladwell on Synta and Oncology
› Perverse Incentives In Clinical Trials
› The Collapse of Complexity
› Rosetta@Home
› Pfizer's Future: Biotech Followups
› Charles River Buys WuXi
› A Landmark In Clinical Trial Data Interpretation
› Pfizer's Golden Age
› Drugs And Their Starting Points
› Merck and Sirna
› Sirtuin Scenarios
› The Cost of New Drugs
› Another Take on the Munos Paper
› Munos On Big Companies and Small Ones
› Pfizer's R&D Productivity
› Selective Scaffolds
› All Of You Industrial Scientists: Out Of the Room
› Recommended Books For Medicinal Chemists, Part One
› Ozonides As Drugs: What Will They Think of Next?
› O Brave New World! That Has Such Companies In't!
› The Drug Business: A Turbulent Future?
› Industrial Research: More Grounded in Reality, or Not?
› To What End?
› Thalidomide for Myeloma: Whose Idea Was It?
› Polymorphs and Salts: India Raises an Eyebrow
› Arzoxifene: Not the Road to Big Profits?
› Spray-Painted For Success
› Pharma's Return on Investment: Yikes
› Drug Approvals, Natural And Unnatural
› How Much Does the Drug Industry Spend on Marketing?
› Eli Lilly Gives It Away
› Medarex, Ipilimumab, Prostate Cancer, And Reality
› One. . .Billion. . .Dollars!
› Funky Carbocycles
› Genzyme's Virus Problems
› More Hot Air From Me on Screening
› The View From Pfizer's Corner Offices
› Ugliness Defined
› A Deuterium Deal
› Akt and Mek, But Not PDQ
› Deuterated Drugs: The PTO Says OK, So Far
› The NIH Takes the Plunge
› Goldman Sachs: Out Of the Drug Funding Business Already?
› Farewell to ACAT, and to Lots of Time and Money, Too
› An HIV Drug. Or A Gout Drug? Or Both. . .
› The Mechanical Chemist?
› Two! Two! Two Drugs in One!
› Gene Expression: You Haven't Been Thinking Big Enough?
› Your Paper Is A Sack Of Raving Nonsense. Thank You.
› Single, Simple Numbers: Use At Your Own Risk
› Heavy Atoms, Heavy Profits?
› A Med-Chem Book Recommendation
› Kinases: Hot or Not?
› Open Pharma?
› Opportunity Costs
› New Year - I Hope!
› Goldman Sachs: A New Drug Research Model?
› Curse Of the Lost Compounds
› Prodrugs: How the Pros Do It?
› Noisy Numbers
› CB-1 Obesity Drugs: Farewell to the Whole Lot
› Down The Chute in Phase III
› Animal Models: How High to Set the Bar?
› Where Are the Drugs?
› Taranabant Is No More
› The Complicated Causes of Cancer
› Samurai! Unleash Your Drug Candidates!
› Sticky Containers, Vanishing Drugs
› Replacing What's Being Lost
› Confident
› Sharing the Enlightenment
› Glaxo Asks the Eurocrats
› Lurching Around For Fun and Profit
› In Which I Hate A Wonder Drug
› "Not Useful" Means "Not Approvable", Right?
› Cordaptive Q and A
› Exubera, Safety, and No Guarantees
› Pre-emption For Real?
› Another Cholesterol Medication Goes Down (Or Does It)?
› Whose Guess Is Better?
› RNA Interference: Even Trickier Than You Thought
› Getting To Lyrica
› That's Never Gonna Work
› Now Your Liver Doesn't Have to Make It For You
› A Solution, Courtesy of the MIT Faculty
› Dissolve Your Troubles Away
› Off Target? Which Target Did You Mean?
› What You Become Known For
› Getting Real With Real Cells
› A Look Under the Hood
› The Animal Testing Hierarchy
› Eat It, Breath It, Soak in It?
› The EU Suspects No One, And Suspects Everyone
› Rainbows and Fishing Expeditions
› Plants For Cancer?
› A Bad Assay: Better Than None?
› Bad Luck For Novartis - And For Diabetics
› Then I Felt Like Some Watcher of the Skies. . .
› You Do The Easy Stuff; I'll Do the Easier
› Quiz Time!
› Here Be Chiral Dragons, With Fluorinated Fangs
› Reasons to Be Different
› Lights, Camera, Pharma!
› Andy Grove: Rich, Famous, Smart and Wrong
› Nerve, Lots and Lots of Nerve
› Resistant Little Creatures
› Bacterial Infection: Better Or Worse Than Cancer?
› Come On. Improve, Already.
› Ugly, But Useful
› Arsenic, Patents, and the World
› Don't Step Over It, Even If It's Right in Front of You
› Drugs From Where?
› Guess That Market
› Renin, Wherefore Art Thou, Renin?
› Elbow Room
› Like Clockwork
› Winning, By Tying Losers Together
› Here, Fix This, Would You?
› Run! Anthropologists!
› You Discover It, We Sell It. Deal?
› From the Sequencer to the Drugstore?
› Deactivation, After All
› A Farewell to Tin
› Bigger, Tougher, Longer? Or Not?
› Less Than Zero
› Awful, No Doubt. But Not As Awful as Before?
› Failure: Not Your Friend, But Definitely Your Companion
› The HDL Compost Pile
› Naked Synthesis
› FDA Advisory Panels: Pay, No Play
› AGI-1067: Dead or Alive?
› No Shortcuts
› Quietly Disappearing From the Skies
› There's Toxicity and There's Toxicity
› Going Hollywood, For Our Own Good?
› What Can Academia Do?
› The Big Picture
› Upside Down Activity
› Reality, Here In This Little Dish
› Bigger And Greasier
› Hope, Springing Eternal And All That
› Experimental Compound Codes
› The Unattractive Truth
› Peptides as Texts
› More Handedness
› A Spray-Painted Crystal Ball
› Ray Kurzweil's Future
› The Sun Shines at Pfizer
› Fuzeon's Fallout
› Disapproval of Approvability
› A Natural Wonder Drug - Now What?
› Have The Rules Changed?
› All Natural
› Heart-Warming Stories of Success
› Kinase Inhibitors: Doomed From the Start?
› If It's Not One Thing. . .
› What Makes an Ugly Molecule?
› Five Questions
› Out the Door and Over the Edge
› Selectivity: One of Those Flexible Concepts
› Another Thing You'd Think Would Be Simple
› Seven Questions
› Morphine in the Brain: Go For It, or Not?
› How Much Success?
› Modeling the Modelers
› Tailfins and All
› Knocking Opportunity Costs
› The Globalization of Med-Chem
› Bigger and Greasier
› How'd We End Up Here, Anyway?
› Hope in a Drum
› The Novartis Way
› Model Systems, From Inside and Out
› Finishing, And Starting
› Proteins to the Rescue?
› DNA to Drug?
› More on Merck
› Drug Development: The Current Odds
› The NIH in the Clinic
› One More On Basic Research and the Clinic
› How Much Basic Research?
› How It Really Works
› Me Too, Part Two
› Down in the Salt Mine
› How Long Can This Go On?
› Worries about Rimonabant?
› Bungee Jumping with PPAR Drugs
› The Two Ends of the Stick
› Down the Hatch
› What Ails Us
› Odd Elements in Drugs: Silicon
› The Vapor Trail I Referred To
› Stuart Schreiber on Stuart Schreiber
› The March of Folly Leader Board
› How Drugs Die
› Sic Transit Gloria Mundi
› New! Improved! Now With Stickier Lumps!
› What Sort of Number Did You Have in Mind?
› Structure-Inactivity Relationship Would Be More Like It
› You Don't Hear "Eureka" That Often
› They All Get Real at Some Point
› Our Buddies at the FDA
› What to Do When the Rats Die on You
› A Twisty Road
› Another Shot
› It's Not Pretty, But It Works
› What's a Project Manager to Do?

Drug Industry History
› The Terrifying Cost of a New Drug
› Putting a Number on Chemical Beauty
› Nowhere to Go But Up?
› The Sirtuin Saga
› Pharma Overview
› Drugs, Airplanes, and Radios
› The Loss of the Middle (Drugs and the People Who Find Them)
› Naming Your Company After Yourself
› Lipitor Expiration Day
› So What Did Lipitor Do for Pfizer? Or Its Shareholders?
› Regeneron Finally Makes It to the Market
› Of Drug Research and Moneyball
› Two From Glaxo's Old Days
› Ray Firestone's Take On Pharma's Plight
› Virtual Pharma, Revisited
› Merck, And What Used to Be Schering-Plough
› Too Many Cancer Drugs? Too Few? About Right?
› Different Drug Companies Make Rather Different Compounds
› Ah, Remember Those Days? How Will We Remember These?
› What Layoffs Have Done
› Targets to Avoid (Or That We Wish We Had)
› Fifty Years of Med-Chem Molecules: What Are They Telling Us?
› A Dish Best Served Cold
› GlaxoSmithKline Reviews the Troops
› Chinese Pharma: No Shortage of Ambition, Anyway
› The Economics of the Drug Industry: Big Can't Be Big Enough?
› Read the Comments
› Bernard Munos Rides Again
› A Former Pfizer Executive Finally Trashes Pfizer's Strategy
› Merck Moving Research From Rahway?
› 2011 Drug Approvals Are Up: We Rule, Right?
› The Secret History of Pfizer
› Phenotypic Screening For the Win
› Innovation and Return (Europe vs. the US)
› The Histamine Code, You Say?
› Drug R&D Spending Now Down (But Look at the History)
› Extreme Outsourcing
› Pfizer's Brave New Med-Chem World
› Maybe It Really Is That Hard?
› Ups and Downs
› A Look Inside the Compound Collections
› Pfizer: Breaking Up Is Hard to Do
› R&D Is For Losers?
› What's Really Killing Pharma
› Value in Structure?
› The Small Drug Companies And the Big Ones
› Pfizer: Bigger, Um, Isn't Better?
› The Costs of Drug Research: Beginning a Rebuttal
› Drug Problems: A Diagnosis
› The Top 200 Drugs
› Too Much Outsourcing: Has the Line Been Crossed?
› Merck's Strategy vs. Pfizer's
› The NIH's New Drug Discovery Center: Heading Into the Swamp?
› What's the Most Worthwhile New Drug Since 1990?
› How to Fund a Nonprofit Drug Company - And Others?
› And So, 2011
› Big Pharma's Lost Stock Market Decade
› Have Pfizer's Investors Had Enough?
› More Advice From Andrew Witty
› Of Deck Chairs, Six Sigma, And What Really Ails Us
› Halaven: Holder of the Record
› Comment of the Day: Outsourcing and Architecture
› Where Drugs Come From: By Country
› Where Drugs Come From: The Numbers
› Well, Okay: The Ugliest Biopharma Sites?
› Most Picturesque Biopharma Location?
› Drug Discovery History
› Princeton's New Chemistry Building
› Serendipity in Medicine
› Avandia Goes Down: A Research Rant
› Columns Outside The Doors
› Going Hollywood
› Not The End. Not At All
› Open-Source Pharmaceutical Babble
› Natural Products: Not the Best Fit for Drugs?
› GSK's Biotechy World
› The Economic Impact of the Genomic Revolution's Failure
› Looking Back at the Genome
› Alzheimer's: Extracting Data From Failed Trials
› The Atlantic Monthly on Drug Pipelines
› Insulin Degrading Enzyme's Turn in the Spotlight
› Malcolm Gladwell on Synta and Oncology
› The Collapse of Complexity
› Two Bad Ideas
› Colchicine's Price Goes Through the Roof
› Too Many Consulting Jobs Work This Way
› Diminishing Returns
› Privileged Scaffolds? How About Unprivileged Ones?
› Privileged Scaffolds
› Where Would You Start a Company?
› More On Pharma's Ugly Finances
› Polluting the Literature with PAINs
› Sheer Economics: How We Got in This Fix
› Remember Apo-A1 Milano? Pfizer Does.
› The Cost of New Drugs
› Another Take on the Munos Paper
› Munos On Big Companies and Small Ones
› Pfizer's R&D Productivity
› Drug Companies Since 1950
› Why Don't We Have More Protein-Protein Drug Molecules?
› Against Panic
› Thoughts on What Used to Be Schering-Plough
› In Which You Get to Hear the Phrase "Hatch-Waxman" Again
› Fifty Years of Scientific History For You
› You Mean You Don't Have to Buy Them?
› O Brave New World! That Has Such Companies In't!
› Fall From Grace
› The Drug Business: A Turbulent Future?
› Sepracor: A Desirable Property?
› Rings of the Future!
› Thalidomide for Myeloma: Whose Idea Was It?
› Drug Companies Are Polar Bears? Maybe Not.
› Spray-Painted For Success
› Pharma's Return on Investment: Yikes
› Where Drugs Come From, and How. Once More, With A Roll of the Eyes
› Amyloid in Trouble
› Drug Approvals, Natural And Unnatural
› Why Does Screening Work At All? (Free Business Proposal Included!)
› How Much Does the Drug Industry Spend on Marketing?
› Jargon Will Save Us All
› GSK's Getting Better. Just Ask the CEO.
› The View From Pfizer's Corner Offices
› CafePharma Will Now Approach The Bench
› Akt and Mek, But Not PDQ
› The NIH Takes the Plunge
› San Francisco Biotech: Holding Up, or Not?
› Book Review Department
› Farewell to ACAT, and to Lots of Time and Money, Too
› Genes to Diseases: Hard Work, You Say?
› Who They?
› Scientists Running Your Drug Company?
› The Mechanical Chemist?
› The Equipment Graveyard
› Drugs For Bacteria: Really That Hard, Or Not?
› Roche / Genentech: The Chase Is Over
› Merck Actually Does It
› Does Glucophage Make Alzheimer's Worse?
› Kinases: Hot or Not?
› Sir James Black Vents, Therapeutically
› A Long Tail Indeed
› Ten Years After: The Genomics Frenzy
› Why Pfizer?
› New Year - I Hope!
› When Placebos Were All There Were
› Curse Of the Lost Compounds
› Novartis and Reality
› Down The Chute in Phase III
› Where Are the Drugs?
› Sunesis: No Substitutions Allowed?
› Replacing What's Being Lost
› Confident
› Pfizer's Prospects: Just Ducky
› A Breath of Fresh Air from Fuji
› Awash in Yen
› Lurching Around For Fun and Profit
› Merck Bails on Natural Products
› O Pioneers!
› Why Buy, Anyway?
› That's Never Gonna Work
› Pen and Paper
› Hits, Misses, and Some More Misses
› Smaller, Wetter, Harder to Work With
› What You Become Known For
› Judah Folkman
› Plants For Cancer?
› Top of the Heap
› Hearing Footsteps
› Med-Chem Layoffs, On the Front Page
› Then I Felt Like Some Watcher of the Skies. . .
› One Year
› Reasons to Be Different
› Lights, Camera, Pharma!
› Andy Grove: Rich, Famous, Smart and Wrong
› Surveying the Exubera Crater
› More Layoffs, And What They Might Mean
› Good News From the HR Department!
› The Good Old CombiChem Days
› Guess That Market
› Renin, Wherefore Art Thou, Renin?
› You Discover It, We Sell It. Deal?
› From the Sequencer to the Drugstore?
› Godzilla vs. Mothra? Relman vs. Epstein!
› First Impressions
› Bigger, Tougher, Longer? Or Not?
› Awful, No Doubt. But Not As Awful as Before?
› Biotech's Net Loss?
› Going Hollywood, For Our Own Good?
› The Big Picture
› Way Out Here
› Novo Nordisk Axes Med-Chem
› Good Stuff and Bad Stuff
› The Paper Mountain
› Help Wanted - I Hope
› Naming of Names
› Experimental Compound Codes
› Peter Kim, So Far
› Chem-Geek Alternate History
› All Natural
› Why All the Gloom?
› Procter and Gamble Throws in the Towel
› But At My Back I Always Hear. . .
› Serono's Suitors
› The Old Stuff
› The Painful History of Substance P
› Room At the Top?
› Biotech At Last, Eh?
› Days of Silicon and Roses
› Some Perspective
› Merck's State of Mind
› Different or Not? You Tell Me.
› Pharma Flock Begins Migration
› Circular Mistakes
› How Much Basic Research?
› The State of the State of the Art
› Loose Lips
› Dumpster Diving for Data?
› What Ails Us
› The Last Word on Taste
› The March of Folly Leader Board
› The March of Folly
› Reality's Revenge
› Ezetimibe, The Press, and More
› The Beginning? It's Right Past the End. . .
› The Old Days, Some Older Than Others
› Here and There
› Thalidomide in the Mirror
› Overpatenting?
› Where Credit's Due
› And I Still Have Some of Those Shirts
› Fun While It Lasted
› Nothing Like It in the World
› Separation Anxiety

Drug Prices
› The Terrifying Cost of a New Drug
› Makena's Market. Or Lack of One.
› More On Cancer Drug Shortages
› Does Anyone Want Axanum?
› Dendreon: Watch the Cost Curve Being Bent
› Drugs for Multiple Sclerosis: Worth the Price, Or Not?
› Avastin and Medicare
› Process Chemistry Makes the Headlines
› Lucentis and Avastin: Results
› Update on Avastin and Lucentis
› KV Pharmaceuticals and Makena: The FDA's Move
› More on KV and Makena's Pricing
› Makena's Price: What to Do?
› The Cost to Develop a Drug: Your Own Numbers?
› That $43 Million R&D Figure
› The Costs of Drug Research: Beginning a Rebuttal
› Use Avastin! Don't Use Avastin!
› Avastin For Metastatic Breast Cancer: The Whole Story
› Going Hollywood
› Drug Prices in the US: Not So High After All?
› Ipilimumab (And Progress Against Cancer)
› Again, What's It Worth to You?
› Pfizer's Future: Biotech Followups
› Colchicine's Price Goes Through the Roof
› In Which You Get to Hear the Phrase "Hatch-Waxman" Again
› Fall From Grace
› Lexapro, Forest Labs, and the Hard Sell
› The PhRMA Deal
› PhRMA's Negotiating Game
› Just Give It to NIH
› Health Care Reform - Really?
› Book Review Department
› Kumbaya
› Direct To Consumer Ads: Wasted Money?
› A Solution, Courtesy of the MIT Faculty
› Drugs and Money
› Laissez-Faire?
› The EU Suspects No One, And Suspects Everyone
› Drugs and Money and How It Feels
› Dollar, Drugs, and Advertising
› Guess That Market
› Godzilla vs. Mothra? Relman vs. Epstein!
› European Drugs, American Drugs
› Brazil Raises The Pirate Flag
› Fuzeon's Fallout
› Price Gouging or Not?
› What's It Worth to You?
› Pfizer Takes a Deep Breath
› Ugly, But Effective
› The Undefeated Brazilian Team
› Brazil Pulls Out the Pin
› Check, Please
› Cui Bono?
› Preach It, Brother
› Prices and Innovation
› Peter Rost, Oddity
› Kicking the Dinosaur's Tail - Again
› Me Too, Part Two
› I'll Have the Price They're Having
› John Kerry on Drug Prices
› Costs and Benefits, Risks and Rewards
› So What's Wrong With A Little Money Changing Hands?
› It'll Cost You
› You'd Think It Was An Election Year or Something
› Price Hydraulics
› Getting the Word Out, For Once
› Welding the Steering Wheel
› More From the Me-Too Front
› Putting A Price on Proving It
› One Of Us Is Hallucinating
› Reimportation's Just the Beginning
› Drug Prices and Costs - From the Mail
› More on Prices, High and Otherwise
› The Contact Sport of Cost Accounting
› Darn Those R&D Costs, Anyway
› From Each According To Their Creativity, To Each According To Their Difficulty?
› The Pricing Weapon
› Good Sense Wins a Round
› More on Drug Prices
› The Dismal Science of Drug Prices

General Scientific News
› Let's Start Off the Meeting With An Ad, OK?
› Strangest Presentation You've Seen?
› Worst Lecture of All, Or Greatest?
› What's the Hardest Thing?
› Very Likely Not Real, But Still. . .(The E-Cat)
› Liquid Handling
› The Singularity, Postponed
› Podcast Interview on Drug Discovery
› Yep, That's A Nobel Prize, Right There
› Chemistry Nobel Time
› The NIH Wonders About the Future of Biomedical Workers
› Gilenya's Price
› Return of the Arsenic Bacterium
› A Google Oddity
› Ups and Downs
› Writing About Science, and Liking It
› Politics in the Lab
› NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
› Arsenic Bacteria: Does The Evidence Hold Up?
› Kitchen Chemistry Gear
› Is Cancer A Disease of the Modern World?
› So, How Well Does Winning a Nobel Set You Up?
› Nobel Season 2010
› Chemical Biology - The Future?
› Know How to Make Praziquantel? Tell The World.
› Lechleiter's Prescription for Science
› Let's Sequence These Guys
› Try It At Home
› Garage Biotech
› A Friday Book Recommendation
› Maybe You Need Some More Testosterone Over There
› Find That Pattern
› Pass the Popcorn
› Copyright 1671: I Like the Sound of That
› Climategate and Scientific Conduct
› Real Electrons
› Real Molecules
› Jargon Will Save Us All
› Altermune - Real Stuff or Not?
› The Mechanical Chemist?
› Fan Mail
› Tie Me Molecule Down, Sport
› Science and Its Values
› Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
› Awkward Conversations
› Enhancing the Brain: Here We Go
› Protein Folding: Complexity to Make More Complexity?
› The Gates Foundation: Dissatisfied With Results?
› Nullius in Verba
› An Eye For the Numbers
› Science By Country
› Getting Smarter Already?
› DNA Forklifts, DNA Pliers
› Room At The Bottom, For Sure
› And Speaking of Discovering Things. . .
› Dumber in English?
› Enzyme Humility
› Unnatural, And Proud Of It
› Winning, By Tying Losers Together
› Hype In Spaaaace!
› The Chamber of DNA Secrets
› The Big Time
› Naked Synthesis
› Inspirational Reading?
› Forty NMR Magnets and 3000 Proteins Later. . .
› Cheer Up, You Chemists
› Another Chemistry Prize for Biology
› RNA Interference: Film at Eleven
› Nobel Update: RNAi Wins
› Nobel Fever Is Upon Us
› By Any Other Name
› If You Want Your Explanations Overnight, It'll Cost You
› Explain This, Hot Shot!
› Ray Kurzweil's Future
› Peptide Craziness
› Pounding Sand
› Aluminum: Friend or Foe?
› Outside Reading
› Attack of the Angry Viruses
› Play by Play in the Lab
› Start Your Engines
› The Tiniest Doors Begin to Open
› Outside Reading
› For Further Enlightenment
› An Off-Topic Ramble
› Why Carbon Matters
› Exobiochemistry
› How Often Do We Land on Another World?
› More Fun With DNA
› Tadpoles to the Rescue?
› Memorial
› The Dull Edge of Nanotech
› A Birthday Worth Noting
› Nuclear Fusion, Wordsworth, German Cooking. The Usual.
› A Request From Biology
› Looking Back, Looking Forward
› Place Your Bets
› Unequivocal Good News
› A New Form of Hype, uh, Life?
› What I, um, Meant to, um, Say
› Left and Right, Revisited
› Y'all Are Going to Think I'm Nuts, But. . .
› The Good Old Days of Really Bad Teeth, Revisited
› Et in Arcadia Ego
› Faces In the Clouds
› Cloning's Growing Pains
› Nobelity and Lesser Nobelity
› Another Stuffed Shirt
› Nobel Time!
› The Bigger They Are
› Our Friend the Phosphate Group, Redux
› Our Friend the Phosphate Group
› A Strange Compound, In Strange Places

Graduate School
› Dealing With Dishonesty
› The UCLA Lab Fatality: Criminal Charges Filed
› The NIH Wonders About the Future of Biomedical Workers
› Sezen / Sames: What Does it Say About Grad School?
› The Fox's Lament
› In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
› The PhD Problem
› The Hours You Put In
› Posters and Pickiness
› How Long Would It Take - If Everything Worked?
› How Much is the PI To Blame?
› Gegen die Dummheit . . .Well, Guess Who Wins, Again
› Reasons Not to Go to Grad School?
› I'll Get Right On That For You, Professor
› Random Questions, Answered Randomly
› The Real Hazards of the Lab
› Out the Door and Down the Stairs
› More Than This
› How Not To Do It: Water Aspirators
› Scrape Off Some Attitude
› And It Goes Like This!
› Looking Backwards
› Understanding Dawns
› Cheer Up
› ". . . Jobs That Don't Exist"
› Pilferage
› The Doctorate and Its Discontents
› Doctorate or Not?
› Fish Nor Fowl?
› Decisions, Decisions
› Depraved and Deprived
› Levoglucosan
› German, Anyone?
› Tenderbutton Calls It Quits
› Spectroscopic Days
› If You Want Your Explanations Overnight, It'll Cost You
› Hobson's Choice
› Academia in Summertime
› Grad School, Blogged
› Arcadia's Furnishings
› Never Came In Handy. Not Once.
› . . .It's a Wonder I Can Think At All
› Industry vs. Academia: The Mental Aspect
› Differences Between Industry and Academia, Pt. 1
› Sweet Maybe, But Trouble, Too
› A Couple of Days Off

How Not to Do It
› Storage of Industrial Chemicals, Gone Rather Wrong
› How Not To Do It: Hydrogen Gas Mixtures
› Max Gergel's Memoirs
› How Not to Do It: Acetylene Cylinders
› Phthalate: A Natural Product? Sure 'Bout That?
› How Not to Do It: Liquid Oxygen Cylinders
› Mental Health Break: The Alkali Metals Show Their Personalities
› Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
› How Not To Do It: The Secret Patent Decoder Ring
› How Not To Do It: Water Aspirators
› How Not To Do It: Diazomethane
› How Not To Do It: Column Chromatography
› How Not to Do It: Hydrogen Bromide
› How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
› How Not to Do It: Tertiary Butyllithium
› How Not To Do It: Ruining Stuff
› How Not to Do It: Sophomore Organic Edition
› How Not to Do It: Distilling HMPA
› How Not to Do It: Liquid Nitrogen Tanks
› How Not to Do It: Ether Peroxides
› How Not to Do It: Bromine
› How Not to Do It: Vacuum Pumps
› How Not to Do It: Distilling Benzene
› Speak for Themselves, They Do
› Ping! Ping! Ping!
› How Not to Do It: Sulfenyl Chlorides
› How Not to Do It: Sodium
› How Not to Do It - Hydrogen Balloons
› Our Friend, the Carbon-Aluminum Bond
› How Not to Do It: Solvent Stills
› Not Like Law School

How To Get a Pharma Job
› Imperfect Pitch
› Walk Around Some
› Making the Adjustment to Smallness
› If Not This, What?
› Hey, Graduates! Negotiate Hard, You Hear, Now?
› ". . . Jobs That Don't Exist"
› More on Interview Seminars
› Starting Up Again
› Fish Nor Fowl?
› Decisions, Decisions
› Have We Got a Job For You!
› Are You Experienced?
› The Other Side of the Table
› Bad Interviews
› Man Hands on Misery to Man
› Here's A Shovel. Could You Dig Yourself In Some More?
› Name Reactions for One Thousand, Alex
› Hire the Thoroughbreds?
› What Sort of Training?
› Dinner the Night Before
› Getting Hired as a PhD
› How To Get Hired: Associate Positions
› Sneaking Out for an Interview
› Getting A Job

In Silico
› Putting a Number on Chemical Beauty
› A Look Into the Future?
› Where's the Best Place to Apply Modeling to Drug Discovery?
› Foldit Notches a Protein Structure Success (And Some Failures)
› Design a Molecule, Win an IPad (Which is More Than You Usually Get)
› Modeling and Structure
› Value in Structure?
› Maybe We Should Make It More of a Game
› Free Software
› What Has Bioinformatics Ever Done For Us?
› Modeling in Drug Discovery: Questions?
› Unlovely Polyphenols
› Bill Gates Put Some Money On Schrödinger
› Another Proposal For the Scientific Literature
› Compounds and Proteins
› We Don't Know Beans About Biotin
› Benford's Law, Revisited
› Selective Scaffolds
› Why Don't We Have More Protein-Protein Drug Molecules?
› Side Effects, Predicted?
› Warren DeLano
› The Further In You Go, The Bigger It Gets
› Why Does Screening Work At All? (Free Business Proposal Included!)
› What's So Special About Ribose?
› Another Thing We Don't Know
› Jargon Will Save Us All
› Mexican Lemons To the Rescue
› The Motions of a Protein
› Structure-Activity: Lather, Rinse, and Repeat
› Floppiness Is Not Your Friend: Who Knew?
› Protein Folding: Complexity to Make More Complexity?
› X-Ray Structures: Handle With Care
› Up Close and Personal
› O Pioneers!
› Start Small, Start Right
› Smaller, Wetter, Harder to Work With
› Melting Keys and Squishy Locks
› No Shortcuts
› Wrong, But Still Convincing
› Love and Anger
› Enzymes Do Whatever They Want To
› Crystals of Doubt
› Molecular Modeling Cage Match
› The Hazards of Molecular Modeling
› Clamping Down, or Loosening Up?
› Crossing Your Fingers, Authoritatively
› Kinases and Their Komplications
› FullCell 1.0?
› The March of Folly
› Reality's Revenge

Infectious Diseases
› The XMRV Story Is Not Getting Any Saner
› Cyclodextrin's Day in the Sun
› XMRV - Work Went On
› XMRV: This Is Not Good
› XMRV: Over With and Done?
› Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
› Kibdelomycin, A New Antibiotic. In A Way.
› DRACOs: New Antivirals Against Pretty Much Everything?
› The Evolution of Resistance: Are We Doing It Wrong?
› Murine Viruses and Chronic Fatigue: Does the Story Continue
› XMRV and Chronic Fatigue: Down For More Than the Third Time
› Process Chemistry Makes the Headlines
› Selenium In a Drug Structure: Why Not?
› Pfizer Moves Antibacterials to Shanghai
› XMRV: It's Ugly, But That's Science
› Chiral What? Chiral How?
› HIV Therapies: A Thank-You
› TRIM21: A Cure For the Common Cold? Maybe Not. . .
› XMRV? Or Umpteen Other Viruses? Or What?
› Know How to Make Praziquantel? Tell The World.
› XMRV and Chronic Fatigue: You Thought You Were Confused Before
› Unlovely Polyphenols
› Rosetta@Home
› A Landmark In Clinical Trial Data Interpretation
› Dundee's NMT Inhibitors for Sleeping Sickness: An Update
› Good News Versus Sleeping Sickness
› Your Own Personal Bacteria
› A Friday Book Recommendation
› XMRV and Chronic Fatigue Syndrome: More Negative Data
› A Pile of Malaria Leads For the Taking
› Two Doses of Crazy
› Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
› Ozonides As Drugs: What Will They Think of Next?
› Chronic Fatigue - Retroviruses to Blame, or Not?
› A Nobel for Ribosome Structure
› A Deuterium Deal
› Altermune - Real Stuff or Not?
› Don't Hit The Bunkers Just Yet
› An HIV Drug. Or A Gout Drug? Or Both. . .
› Two! Two! Two Drugs in One!
› Drugs For Bacteria: Really That Hard, Or Not?
› A Quick Quiz (Re: Antibacterials)
› Bacteria: Respect Must Be Paid
› A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
› Maribavir, Ouch
› Fun With Bacteria
› Another Cholesterol Medication Goes Down (Or Does It)?
› Whose Guess Is Better?
› Smaller, Wetter, Harder to Work With
› Resistant Little Creatures
› Bacterial Infection: Better Or Worse Than Cancer?
› Now With Ethyl Mesylate!
› Evolution In Action
› Brazil Raises The Pirate Flag
› A New HIV Therapy. Yawn?
› Deep Breaths
› Vertex, Hepatitis, and Gripping the Arms of Your Chair
› Peptides as Texts
› Enzymes Do Whatever They Want To
› Fuzeon's Fallout
› A New Route to Tamiflu?
› Tamiflu: Good For Anything, Or Not?
› One Darn Miracle After Another
› Cash For Vaccines
› The Flu Plan, Part Two: Antiviral Drugs
› The Flu Plan, Part One: Vaccines
› Buy! It's More Expensive Than Usual!
› Well Deserved
› Antivirals "Gathering Dust"?
› The Check Shows Up in the Mail. Really.
› And It Goes Like This
› More on Brazil and Kaletra
› Brazil Pulls Out the Pin
› Where's the Combo?
› Fan Mail
› Pfizer Opens Their Wallet - Again
› Fungal Problems
› Dr. Rath Does What He Can
› Vertex Turns Over a Winner
› Do It Again
› An Antiviral Example
› Can Med-Chem Help With Bird Flu?
› Empty Shelves
› Resistance to Resistance
› It's a Bacterial Planet, You Know
› They Will Do Such Things. . .
› A Last-Ditch Effort - Or Is It?
› Better Them Than Me
› A Twisty Road
› New! Viruses So Potent, You'd Swear They Were Homemade!
› If It Were Easy. . .
› New Drugs for HIV

Inorganic Chemistry
› Surfin' On The Surface
› Neil Bartlett, 1932-2008
› Copper: A Gentleman's Disagreement
› A Salute

Intelligent Design
› Unintelligent Design
› Brief Political Interlude
› Ban Intelligent Design?
› Poor Put-Upon Intelligent Design
› The Dover Decision Comes Down
› Intelligent Design, Molecule By Molecule
› The Dover Decision
› An Off-Topic Ramble
› Intelligent Chemical Design

Life As We (Don't) Know It
› Arsenic Bacteria Ride Again. (Or Don't).
› A First Step Toward A New Form of Life
› Arsenic in DNA: The Kinetic Argument.
› Life With Arsenic: Who'd Have Thought?
› Chemical Biology - The Future?
› Let's Sequence These Guys
› Friday Book Recommendation
› What's So Special About Ribose?
› Mass Spec on Mars
› Intelligent Chemical Design
› Exobiochemistry
› Our Friend the Phosphate Group
› Mirror Stars

Life in the Drug Labs
› Potassium Hydride Is Not Your Friend
› The Future of Pharma? Yikes.
› Putting a Number on Chemical Beauty
› Open Office Plans - A Question or Two
› This All Too Open Office
› The Research World Staggers Back to Work
› Uranium, Eh?
› Rating A Massive Pile of Compounds
› Fish Nor Fowl
› Tossing Out the 1920s Hydrogenators: Can It Be Done?
› Fifty Years of Med-Chem Molecules: What Are They Telling Us?
› From the RSC/SCI Symposium: A Med-Chem Anomaly
› Disappearing Information, Courtesy of Aldrich Chemical
› Drug Research Areas You Wish You'd Never Heard Of
› High Pressure - The Good Kind
› Chem-Geekery: Name Reactions You've Never Run
› Underused Lab Solvents
› Pfizer's Brave New Med-Chem World
› What Would You Get Rid Of?
› A Complete Diversion: Purple Compounds
› What Medicinal Chemists Really Make
› Return of the Magic Methyl Group
› In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
› Surely You Have Something Else to Do
› A 200-Proof Shot of Medicinal Chemistry
› Brave New Office
› It's Worth It to Know That There Are Others
› Dogs and Ponys
› Fluorination Without Tears. Or Panicked Shouts.
› A Quick Glassware Question
› Novartis and the Labs of the Future
› Comment of the Day: Outsourcing and Architecture
› Good Old Medicinal Chemistry: What Can You Get Away With?
› Shine A Light
› Enthalpy and Entropy Again
› Settle A Bet
› If You're Not Excited, Sit Down
› Keeping Track Of All Those Chemicals
› Palladium Couplings: You Can't Run Them All
› Conference Thoughts
› Workhorse Reactions
› Put In Another Methyl Group: A Villanelle
› Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
› Intermediates
› How Much Compound?
› Nanopowders?
› Sparteine and Other Fine Chemical Shortages
› A Quick And Nerdy Question
› Curse of the Plastic Tubes
› Compounds and Proteins
› Privileged Scaffolds? How About Unprivileged Ones?
› The Chemical Suppliers: Customer Reviews
› Good Suppliers - And The Other Guys
› Science Buildings: Good, Bad, and Weird
› Not Gonna Make That One
› Flowing, Not So Gently
› Cranking Away
› Chemical Supplier Question
› The Infinitely Active Impurity
› In Hoc Signo Non Vinces
› What Should Non-Chemists Know About Medicinal Chemistry, Anyway?
› Oxford's New Building, One Year Later
› Data, Raw and Otherwise
› Recommended Books For Medicinal Chemists, Part One
› Fear Of Academic Chemistry?
› But These Reagents, Where Are They?
› What Are the Best Med-Chem Books?
› Lumpy Assay Results
› Lab Equipment: Any H-Cube Troubleshooters Out There?
› Four Med-Chem Questions
› Reduce Your Number of Reductions, Why Don't You?
› Elements I Have Yet to Use
› Consultants
› Hoist, Petard, Etc.
› Retire These Reactions!
› Colorful Junk
› Sulfoxides: A Sneaking Affection
› How A Real Drug Industry Project Meeting Goes
› Everything In Its Place
› RUR
› Funky Carbocycles
› Ugliness Defined
› Don't Make Them in the First Place?
› Random Questions, Answered Randomly
› Instant Med-Chem Wisdom
› Ever Have One of Those Days?
› Wait For It. . .Wait For It. . .
› Surfin' On The Surface
› The Mechanical Chemist?
› The Equipment Graveyard
› Your Temperamental Diva Reactions
› How Good (or Bad?) Are Patent Procedures, Anyway?
› Hot Chemistry, Low Tech to High
› Inspiration Is Where You Find It
› Structure-Activity: Lather, Rinse, and Repeat
› The Limits of Free Scientist Chow?
› Supplies of Suppliers
› Prep TLC: The Good Old Days Live On
› Fancy Building, Fancy Science?
› The Real Hazards of the Lab
› Lack of Experience, You Know
› Poor Equipment Revisited
› The Perils of Poor Equipment
› The Yield Monster - And Its Friend, The Model Monster
› We Now Return to Our Regularly Scheduled Program
› Out the Door and Down the Stairs
› Fearful Symmetry?
› Old School - Really Old
› Why Don't You Just. . .
› Sugars: Still Crazy After All These Years
› How Not To Do It: Water Aspirators
› Fighting Boredom, Profitably
› Questions You Don't Necessarily Want the Answers To . . .
› Backtracking, Necessary and Unnecessary
› Lowe's Law of Diurnal Distribution
› How's The New Boss Doing?
› I Can Has Ugly Molecules?
› Tote That Barge, Lift That Bale
› Oops
› Ah, Glassware
› The Miracle Solvent
› Copper: A Gentleman's Disagreement
› Summer Student Time
› Explaining It All
› Naming of Names
› Walk Around Some
› A Meditation on Solvents
› Another Pop Quiz!
› The Lucky Bonus Pack
› Putting Out the Inevitable Fires
› One Time Only. Or Maybe Just a Few.
› Write It Down, Write it Down
› Dig the New Breed
› A Few Questions For My Fellow Pharma Chemists
› Extractions: A Way of Life
› Cheap Happiness
› Winterize Your Ideas
› Scrape Off Some Attitude
› Underperforming Triple Bonds
› The Big and the Little
› Still and All
› You Do The Easy Stuff; I'll Do the Easier
› Maybe Not Improved, But Definitely New
› How You Doin'? How's Everybody Doin'?
› Here Be Chiral Dragons, With Fluorinated Fangs
› Looking Backwards
› No Problem At All
› Go With The Er, Flow?
› Don't Step Over It, Even If It's Right in Front of You
› Fresh Air, Or What Passes For It
› Aromatherapy
› Here It Goes
› These You Shall Have Always With You
› Run! Anthropologists!
› A Farewell to Tin
› Over There, Behind That Stack of Whatchamacallits
› Starting Up Again
› Sunbeams, Single Electrons, and You
› Safer Every Day!
› Forewarned is Forearmed
› The Doctorate and Its Discontents
› Doctorate or Not?
› Sulfur, Your Pal. Mostly.
› I Want A New Nitro
› Lousy Reactions: Reader's Choice
› Something From Nothing
› Wake Up and Smell the Solvents
› Problems and Solutions
› Good Stuff and Bad Stuff
› You'll Be Safe Under Here. Maybe.
› Cleans Down to What Should Be the Shine
› Old School? Same School!
› Family Portraits
› Five Things I Haven't Used in Years
› Test Your Skills!
› By Any Other Name
› The Last Word on Eerie Glowing Labs
› The Future is Unwritten
› More Purple Radiance
› Memo to the Public Relations Department
› Best When Used By. . .
› A Day at the Rota-Vap
› Sulfurous Stenches: A Connisseur's Guide
› The Process of Process
› Cleaning Out the Hood: An Internal Monologue
› Grad School, Blogged
› First Slide, Please
› Stream of Consciousness
› The Good New Days
› Gimme That Old Time Reaction
› Sort Of Like A Wine Cellar
› Home Sweet Home
› . . .And That Settles It
› Gooooaaaal!
› The Latest in Pharmaceutical Technology
› Tribes
› A Sensitive Guy
› Having the Hands
› Differences Between Academia and Industry, Pt. 4
› Let's Check This Blank Page, Here
› Seven Questions
› Hydrogenation Made Easy?
› How Safe Is This Stuff?
› The Voice of Experience
› Cuprate Voodoo
› Sneaking Out for an Interview
› A Smelly Riddle
› Lost Arts
› Ten Questions
› Ancient Metals
› The Latest from the Fume Hood
› Law and Disorder
› Does Your Labmate Have the Hands?
› Glassware Geek
› Through the Looking Plastic
› Our Friend the Nitrogen Atom
› Lab of the Future!
› Beg to Differ
› Chemistry Geekery
› Nine Things I'm Having Trouble Imagining
› A Visit To Academia
› Well, Sonny, That's Not How We Did It
› It's All Local, All Right
› A Spin of the Wheel
› Ping! Ping! Ping!
› A Day in the Life: Dichloromethane and Peanut Butter
› Public Utility, You Say?
› We Have Ways of Keeping You Safe
› Measure for Mismeasure
› Rational Drug Design
› A Week in the Life
› Solid Citizens
› Lighting Out for the Frontier
› Wipe Down
› The Latest From the Fishing Hole
› Catalyst Catfishing
› Next on the Food Channel. . .
› The Last Word on Taste
› Beyond the Teeth, Beyond the Pale
› By Any Other Name
› At My Desk, Playing 500-Card Stud
› Mutter, Mutter, Mutter
› Obvious to One Skilled in the Art
› Quis custodiet ipsos custodes?
› A Quick One While He's Away
› A Chemical Wish List
› Multitasking
› Idle Hands
› And I Still Have Some of Those Shirts
› Talk, Cheap and Otherwise
› More Pfizer Explosion Details
› Blowups Happen
› Another Shot
› A Clean Lab is A Happy Lab
› Back to Whatever It Is I Do
› Colors May Fade
› More Colors and Smells

Lowe's Laws of the Lab
› Prediction Markets, Idea Sharing, and So On
› Cheese Dip and Hydrochloric Acid
› A Law of the Lab: Yields and Variations
› Yet Another Law
› Another Law of the Lab
› Think Twice
› Law Number One

Metaphors, Good and Bad
› Block That Metaphor!
› Melting Keys and Squishy Locks

Natural Products
› Kibdelomycin, A New Antibiotic. In A Way.
› Chiral What? Chiral How?
› And One Was Just Right?
› Vinca Alkaloids, And Where They End Up

Odd Elements in Drugs
› Selenium In a Drug Structure: Why Not?
› You Don't See Many Names Starting with "Tellura-"
› Ozonides As Drugs: What Will They Think of Next?
› One For the Brave
› Arsenic, Patents, and the World
› My Shopping List
› Odd Elements in Drugs: Silicon
› Odd Elements in Drugs

Patents and IP
› Academia and Industry, Suing Each Other
› Don't Dose That Patient Until You Pay Up
› Amgen's New Patent: Explanations, Anyone?
› A New Book on Chemical Patents
› Patent Trolling, Money and Fun
› A Dish Best Served Cold
› Chinese Research: Not Quite the Juggernaut?
› Roche Prevails Over Stanford
› Roche and Stanford: Academia v. Industry?
› Freedom to Operate
› Are Genes Patentable Or Not?
› Apotex's Plavix Adventure: Four Years Later
› You May Not Be Interested In It - But It's Interested In You
› Running Out of Decent Molecules to Patent?
› Patent Chart Update
› Take These?
› Only Three Patents? Really?
› The Ariad Decision and Written Description
› Myriad's BRCA Gene Case: Wait For It
› Ariad Loses on Appeal
› Drug Patents in India
› Acorda and Ampyra
› So, Do I Own This, Or What? Answer: What
› In Which You Get to Hear the Phrase "Hatch-Waxman" Again
› How To Get Useful Data Out of a Drug Patent
› Ignoring Patents?
› Thalidomide for Myeloma: Whose Idea Was It?
› Ariad's Patent Rises From the Grave to Smite the Living
› Polymorphs and Salts: India Raises an Eyebrow
› How Not To Do It: The Secret Patent Decoder Ring
› Professors Patent Pathways and Possibly Profit? Please.
› Perpetual Patents: A Nasty Thought Occurs
› Perpetual Patent Motion Machine
› Deuterated Drugs: The PTO Says OK, So Far
› Ariad's Patent: Let Us Now Dance In Circles
› How Good (or Bad?) Are Patent Procedures, Anyway?
› Ariad's Patent: A Court Rules
› Rember for Alzheimer's: Methylene Blue's Comeback
› Confident
› Patents Stopping an Alzheimer's Wonder Drug?
› Unknown - But You Can Buy It
› Hearing Footsteps
› Fixing the Patent System?
› Ugly, But Useful
› Arsenic, Patents, and the World
› Nonsense. On Stilts. Playing a Trumpet.
› Brazil Raises The Pirate Flag
› Obvious Ain't Obvious No More
› Crichton, Patents, and Genes
› The Paper Mountain
› Show What You Know
› Inherently Obvious - It's Obviously Inherent
› Move On, Move On - Nothing To See Here. . .
› Ariad's Patent Eviscerated
› Plavix Plot Twists
› Respect! Honor! Recognition! All For $149.95!
› The Great Plavix Disaster
› Getting and Spending
› Ariad Wins a Round
› Full Disclosure
› A Shot Across the Bow
› Ariad's Day in Court
› Once More Into the Patent Breech
› Down With Patents, Eh?
› Ah, It's Fine. Just Send the Darn Thing Out Already.
› The Examiner Finally Snaps
› Arr, Me Hearties!
› The Leash of the Law
› Brazil Pulls Out the Pin
› Vaccines and Human Folly
› The Research Exemption Lives!
› Merck and Integra Go the Distance
› Between Friends. Sort of.
› Back For More
› Dysfunctional Disclosure
› Elbow Room
› Merck Takes Another One
› Success Has A Thousand Fathers
› Fixing the Drug Industry?
› Keep It To Yourself
› I'll Have the Lot
› Alexander Would Have Understood
› Hey, I Could Patent That. . .
› Will the Uncommon Work for the Common Good?
› Living by the IP Sword
› Back for More
› Lighting Out for the Frontier
› Doublets, Triplets, Whateverlets
› This Isn't the Kind of Office Action You're Thinking Of
› All the Myriad Ways
› Owning the Road
› Why Own the Car, When You Can Own the Road?
› Oblivious to One Skilled in the Art
› Obvious to One Skilled in the Art
› How to Be an Inventor
› From Each According To Their Creativity, To Each According To Their Difficulty?
› And Now for Something Completely Different
›